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SCENTIFIC BACKGROUND 
 
COELIAC DISEASE 
Coeliac Disease (CD), also called gluten-sensitive enteropathy, is a 
permanent intestinal intolerance to dietary wheat gliadin and similar 
prolamins from rye and barley (the toxicity of oats has been reassessed in 
recent years), that produces mucosal lesions in genetically susceptible 
individuals.  
  
Epidemiology 
Following the original description that gluten is the agent that causes 
CD (Dicke WK 1953), a better understanding of the clinical aspects of CD, 
and the availability of serological tests to detect CD-associated antibodies, 
have contributed to a significantly improved diagnosis and management of 
the disease. CD represents one of the most frequent genetic diseases of 
humankind. Recently, it has become clear that CD is much more prevalent 
than previously thought, when the reported prevalence of symptomatic CD 
is l in 1000 live births, with a range from l in 250 (observed in Sweden) to l 
in 4000 (observed in Denmark) (Greco L 1992). Population based 
screening studies have clearly shown that CD is underdiagnosed, clinical 
CD representing the top of the iceberg. In fact, these studies have 
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demonstrated the worldwide prevalence to be 1 in 266 (Fasano A 2001). In 
particular, the prevalence of CD is estimated in the range of 1:100 to 1:300 
individuals in the European general population. Similar prevalence have 
been indicated in North Africa, in South America and in USA (Fasano A 
2001, Maki M 2003, Ciclitera PJ 2005). In recent study conducted in the 
United States, Fasano A and colleagues (Fasano 2003) observed that in at 
risk groups CD occurs in 1 of 22 of first-degree relatives, in 1 of 39 of 
second-degree relatives and in 1 of 56 in symptomatic patients. The overall 
prevalence of CD in not-at-risk group is 1:133 (Fasano A 2003). 
Interestingly, during the last few years many studies report a “new 
epidemiology of CD”,  showing that it is common not only in Europe and 
in people of European ancestry,  but also in the developing countries, such 
as Southern Asia, The Middle East, North West and East Africa, South 
America, both in the general population and in the groups at risk (Cataldo F 
2007). 
 
Genetics 
Coeliac disease is a typical multifactorial disease in which both several 
genetic and environmental factors are needed for the disease onset. The 
familial clustering is demonstrated by disease prevalence of about 10% 
among the first degree relatives which is ten fold higher than the risk of CD 
at the general population level. The prevalence was further corroborated by 
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two large population-based twin studies in the Italian population, which 
found a concordance rate in dizygotic twins of around 20% and in 
monozygotic twins of around 85% (Greco L 2002, Nistico L 2006). The 
increase in concordance between twins and the fact that monozygotic twins 
do not have a 100% concordance rate suggest the involvement of 
environmental factors in addition to genetic factors.  
The involvement of HLA complex located in the major 
histocompatibility complex (MCH) region on chromosome 6, which 
predisposes to CD, has been known for over 30 years (Falchuk ZM 1972, 
Stokes PL 1972). In particular, convergent evidence from different 
populations has suggested that the primary association of CD is with the 
HLA-DQ2 (coded by alleles DQA1*05, DQB1*02, inherited either in cis 
or trans) or the HLA-DQ8 heterodimers (coded by alleles DQA1*03, 
DQB1*0302) with respective DR-DQ haplotypes (Sollid ML 1989, 
Mantovani V 1993). Among 1008 European CD patients, 88% carried 
DQ2, 6% were DQ2-DQ8+, 5.6% carried “half” DQ2, i.e. either the 
DQA1*05 or DQB1*02, and only 0.4% of patients were totally negative 
for DQ2 and DQ8 coding alleles (Karell K 2003). A gene dosage effect has 
been suggested, and a molecular hypothesis for such phenomenon has been 
proposed based on the impact of the number and quality of the HLA DQ2 
molecules on gluten peptide presentation to T cells (Karell K 2003, Louka 
AS 2002). The most likely mechanism to explain the association with HLA 
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class II genes is, in fact, that the DQ molecule binds a peptide fragment of 
an antigen involved in the pathogenesis of CD to present it to T cells. DQ2 
and DQ8 are, however, common also in the healthy population, each with 
carrier frequencies of approximately 20-30% among Caucasians. The 
estimated contribution of the HLA region on developing CD is around 40% 
(Bevan S 1999), meaning the remaining 60% of genetic factors involved in 
CD is not well known. Chromosome 5q31-33 region markers (CELIAC2 
locus) have shown genetic linkage to coeliac disease in several genome 
wide analyses and their replication studies. Significant linkage to this 
chromosomal region was identified  in Italian (Greco L 2001), Swedish-
Norwegian (Naluai At 2001), Finnish (Liu J 2002), Irish (Zhong F 1996), 
as well as in Dutch population (van Belzen MJ 2003). This region contains 
a cytokine gene cluster and it might play a role in immune regulation and 
inflammation. The CELIAC3 locus on chromosome 2q33 has shown 
linkage to CD and was replicated by a few but not all the studies performed 
(Victorien M 2008). The CELIAC 3 locus contains the T lymphocyte 
regulatory genes CD28, CTLA4 and ICOS. Recently, a novel candidate 
gene myosin IXb (MYO9B) on chromosome 19p13 (CELIAC4 locus) was 
found in the Dutch population (Monsuur AJ 2005). Interestingly, MYO9B 
is a good candidate gene for CD because of its function; it encodes an 
unconventional myosin molecule that may have a role in actin remodelling 
of epithelial enterocytes. The gene may therefore be potentially relevant in 
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intestinal barrier integrity. However, in CD population in the United 
Kingdom, Spain, Italy and Scandinavia could not be replicated (Victorien 
M 2008). A new genetic association between factor V Leiden and CD was 
discovered (Mari T 2006).  
With recent advances in genotyping technology, the whole genome 
association studies with hundreds of thousands SNPs have become feasible. 
Although they require big sample cohort and are therefore still very 
expansive to perform, the strategy has revealed already promising results in 
finding also genes of relatively low risk effects in many complex disease. 
Recently, the first genome-wide associated study (van Hell DA 2007) and 
its follow up (Hunt KA 2008) have identified eight new loci that contribute 
significantly towards coeliac disease risk. Seven of these contain genes 
controlling adaptive immune response, including IL2/IL21 (4q27), RGS1 
(1q31), IL18RAP (2q11-2q12), CCR3 (3p21), IL12A (3q25-3q26), 
TAGAP (6q25) and SH2B3 (12q24). Wijmenga C and colleagues  
(Romanos J 2008) in Italian cohort showed that common variation in 
IL2/IL21, RGS1, IL12A/SCHIP and SH2B3 was associated with 
susceptibility to coeliac disease. The LPP and TAGAP regions also showed 
moderate association, whereas there was no association with CCR3 and 
IL18RAP. These results may imply there is a genuine population difference 
across Europe regarding the loci contributing to coeliac disease. 
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 However, linkage peaks observed in non-HLA regions are much lower 
and not consistent compared to HLA. This might be because many non-
HLA genes contribute to the pathogenesis of CD. Hence, the contribution 
of a single predisposing non-HLA gene might be modest. 
 
Clinical presentation 
Typical clinical manifestations of CD include chronic diarrhoea, 
abdominal distension, weight loss, anorexia and irritability. Intestinal 
symptoms are common in children diagnosed within the first two years of 
life. Within weeks to months of starting to introduction of gluten in the diet 
these symptoms can be observed (Fasano A 2005). A coeliac crisis, 
characterized by explosive watery diarrhea, marked abdominal distension, 
dehydration and shock, described more commonly at the beginning of this 
century, is now observed rarely.    
CD presenting features later in childhood and in adult patients are 
characterized by the prevalence of unusual intestinal complaints (e.g. 
recurrent abdominal pain, nausea, bloating and constipation) and/or extra-
digestive symptoms including short stature, delayed puberty, anemia, 
dental enamel defects, skin lesions, isolated hypertransaminasemia, bone 
pains and fractures, arthritis, infertility, recurrent fetal loss, and aphthous 
ulceration. In addition, a variety of neuropsychiatric conditions such as 
depression, anxiety, peripheral neuropathy, ataxia, epilepsy with or without 
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cerebral calcifications, and migraine headaches have been reported in 
individuals with CD. A recent study reports considerable changes in the 
age at presentation and the presenting features of CD in children over the 
past 20 years (Ravikumara M 2006). The incidence of CD and the age at 
diagnosis have risen. Gastrointestinal manifestations as presenting features 
have decreased dramatically (between 1999 and 2004, only 42% of 
children had gastrointestinal manifestations, compared with 75%-88% of 
children diagnosed between 1983-1998), while the symptoms at diagnosis 
have become fewer and less severe (Ravikumara M 2006). Data from 
studies on adults are similar, with Lo et al (Lo W 2003) reporting that of 
227 patients only 43% presented with diarrhoea after 1993 compared with 
73% before 1993. 
Different may be the mechanisms operating in these different situations. 
Such extradigestive manifestations may more likely result from the 
intestinal damage and consequent nutritional deficiencies (e.g. anemia, 
osteopenia) and/or due to the deranged (auto?)immune response (e.g. skin, 
liver, joints, CNS involvement).  
Finally, it has become evident, mostly from family studies, that CD may 
be completely silent clinically (Auricchio S 1988). Large numbers of silent 
cases of CD have been reported in at-risk groups (such as patients with 
insulin-dependent diabetes and first-degree relatives) and in general 
population samples enrolled in screening programs. In paediatric age, 
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almost 25% of children with CD are diagnosed  by targeted screening of 
high-risk group and this group is symptom free at diagnosis (Ravikumara 
M 2006). Villous atrophy occasionally may be detected by endoscopy and 
biopsy conducted for another reason: a recent study reports a prevalence of 
1.5% of CD in patients with dyspepsia, a symptom not typically associated 
with CD, concluding that it may be appropriate to recommend the CD 
screening for the patients with refractory dyspepsia (Ozaslan E 2007). 
Particularly close associations have been reported between coeliac 
disease and various diseases, many with an autoimmune pathogenesis, such 
as thyroid diseases (Mulder CJJ 1988),  Addison's disease (Reunala T 
1987), pernicious anemia (Stene-Larsen G 1988), autoimmune 
thrombocytopenia (Stenhammar L 1988), sarcoidosis (Douglas ID 1984), 
insulin-dependent diabetes mellitus (Savilahti E 1986), alopecia (Corazza 
GR 1995) and cardiomyopathies (Not T  2003). Coeliac disease has been 
shown to co-exist with Down’s (Carlsson A 1998, Bonamico M  2001) and 
Turner’s syndrome (Bonamico M 2002). Further, it has been reported that 
1.7-2.6% of coeliac disease patients have selective serum IgA deficiency 
(Cataldo F 1998). In all these groups silent CD is often present. 
Whether the mode of presentation of CD correlates with the degree of 
villous atrophy is still controversial. Previous studies have demonstrated an 
association of severity of histological findings and mode of presentation, in 
particular the authors concluded that more severe clinical symptoms are 
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better predictors of a more severe form of small bowel histopathology in 
children and in young patients (Weizman Z 1997, Tursi A 2002). A recent 
study, that included many more patients than the previous studies (a cohort 
consisted of 449 adult CD patients vs 144 and 59 respectively), does not 
confirm this correlation. The authors, correlating of mode of presentation 
(classical, diarrhoea predominant or atypical/silent) with histology of 
duodenal biopsies, concluded that the clinical presentation does not 
correlate with histological findings (Brar P 2007).  
 
Diagnostic criteria 
In 1969, ESPGAN recommended three intestinal biopsies for the 
diagnosis of CD in childhood: one performed at the time of presentation, 
another after the patient has been on a gluten-free diet when the mucosa is 
expected to have returned to normal, and the final biopsy after the patient 
has been rechallenged with gluten, when villous atrophy is expected to 
have recurred (Meeuwisse G 1970). Twenty years later a working group 
from the ESPGAN reconsidered such diagnostic criteria (Working Group 
of ESPGAN 1990). The two requirements mandatory for the diagnosis of 
CD remain: 1) the finding of villous atrophy with hyperplasia of the crypts 
and abnormal surface epithelium (Fig. 1), while the patient is eating 
adequate amounts of gluten; and 2) a full clinical remission after 
withdrawal of gluten from the diet. The finding of circulating IgA 
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antibodies to gliadin, reticulin, and endomysium at the time of diagnosis, 
and their disappearance on a gluten-free diet, adds weight to the diagnosis. 
A control biopsy to verify the consequences on the mucosal architecture of 
the gluten-free diet is considered mandatory only in patients with equivocal 
clinical response to the diet and in patients asymptomatic at first 
presentation (as is often the case in patients diagnosed during screening 
programs, e.g., first-degree relatives of coeliac patients) (Working Group of 
ESPGAN 1990).  
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FIG.1 (A) Hematoxylin-eosin (H&E)-stained section of a normal small intestinal biopsy. It shows villi 
(V) and crypts (C). the lamina propria (LP) extends between the crypts and into the core of each villous, 
and it contains a rich vascular and lymphatic network into which digestive products are absorbed. 
Original magnification, x 400. (B) H&E-stained section of a small intestinal mucosa biopsy from an 
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individual with CD. Note villous atrophy, enlarged hyperplastic crypts and increased infiltration of 
lymphoid cells in lamina propria and epithelium.   
 
Challenge is not considered mandatory, except under unusual 
circumstances. These include situations where there is doubt about the 
initial diagnosis, for example when no initial biopsy was done, or when the 
biopsy specimen was inadequate or not typical of CD. Again, the 
diagnostic gluten provocation may be necessary to exclude other causes of 
enteropathy, such as cow’s milk sensitive enteropathy, postenteritis 
syndrome, and giardiasis that could be responsible for the flat mucosa. 
These disorders frequently occur in the first 2 years of life, for this reason 
gluten challenge is recommended in children younger than 2 years of age 
gluten provocation (Working Group of ESPGAN 1990). Gluten challenge 
should be discouraged before the age of 7 years and during the pubertal 
growth spurt. Once decided, gluten challenge should always been 
performed under strict medical supervision. It should be preceded by an 
assessment of mucosal histology and performed with a standard dose of at 
least 10 g of gluten per day without disrupting established dietary habits. A 
further biopsy is taken when there is a noticeable clinical relapse or, in any 
event, after 3 to 6 months. Serologic tests (IgA gliadin, reticulin and 
endomysium antibodies, absorptive and permeability tests), more than 
clinical symptoms, can be of help in assessing the timing of the biopsy to 
shorten the duration of the challenge (Mayer M 1989). 
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It is now quite widely accepted that the development of the CD mucosal 
lesion is a dynamic process, so there is a range of histological changes from 
normal villous architecture with an epithelial lymphocytosis, through 
partial villous atrophy to total villous atrophy (Marsh MN 1992). In a 
situation where jejunal histology has lost specificity, and with the growing 
contribution by serology, and to a less extent by HLA, many propose to 
move to a new diagnostic approach mainly based on antibodies and 
genetics.  
According to recently published guidelines, serologic testing is of 
primary importance to screen patients for biopsy and follow response to 
treatment (Hill ID 2005). IgA anti-human recombinant tissue 
transglutaminase antibodies (TG2-HR) detected by enzyme-linked 
immunosorbent assay (ELISA) and IgA endomysial antibodies (EMA) seen 
on monkey esophagus (ME) or human umbilical cord (HUC) substrates by 
indirect immunofluorescence are considered the most sensitive and specific 
serologic test for CD (Hill ID 2005, Rostom A 2005). It is well-established 
that increased EMA and TG2 in both children and adults correlate with 
abnormal small bowel histopathology (Rostami K 1999, Sategna-Guidetti 
C 1993, Abrams JA 2004). Tursi et al (Tursi a 2003) observed in adult 
people that the prevalence of TG2 and their mean serum value were higher 
in CD patients with severe enteropathy (Marsh 3b-c) than in those showing 
slight enteropathy (Marsh 1-3a). In a study  of 30 children it is reported a 
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correlation between TG2 antibody titer and Marsh score (Hoffenberg EJ 
2000). Only recently, Donaldson MR et al report levels of serum antibodies 
that were nearly always associated with severe enteropathy. They confirm 
that IgA TG2 and EMA levels correlate with duodenal villous atrophy in 
pediatric CD patients and observe that strongly positive antibodies levels 
(TG2 >100 units and/or EMA titer >1:1280) are highly specific (>98%) for 
Marsh 3a or greater lesions (Donaldson MR 2007).   
Because more than 98% of people with coeliac disease share the major 
histocompatibility complex II class HLA-DQ2 or DQ8 haplotype, the 
inclusion of HLA typing for these haplotypes is useful, especially in 
particular situations. In fact,  HLA-DQ2 OR HLA-DQ8, or both, are found 
in approximately 40 percent of the general population, but in more than 99 
percent of coeliac patients. People who do not have HLA-DQ2 or HLA-
DQ8 haplotypes are unlikely to have coeliac disease (Kaukinen K et al 
2002).  
In conclusion, considering that more  than  40% of the population has 
the HLA alleles implicated in coeliac disease and more than 1% a positive 
serology, with an increasing number of subjects showing signs of minor 
enteropathy, the analysis of jejunal biopsies is still very important 
instrument for the diagnosis of coeliac disease. So, until serological 
methods are improved,  the  genetic make up of coeliac patients is better 
defined, it seems wise for a diagnosis of coeliac disease still rely on a 
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combined approach based of clinical criteria,  histology, serology and 
genetics. 
  
 “Potential” Coeliac Disease  
 The development of the CD mucosal lesion is a dynamic process that 
may present in various stages or types of lesions and in duodenal biopsy 
with a normal architecture, an increase in the number of IEL can be the first 
and most sensitive index of the effects of gluten on the mucosa and can be 
therefore the single most important histological feature in CD (Marsh MN 
1992).  It is well known that intraepithelial lymphocytosis are increased in 
the mucosa of untreated coeliac patients, but these cells are not 
pathognomic for CD, as their density can be elevated on other disorders, 
such as autoimmune diseases and in patients that use nonsteroidal anti-
inflammatory drugs. However, about in nearly 10% of cases can be the 
initial presentation of CD (Kakar S 2003). Certainly, an increase of δγ + 
IELs in the presence of villous atrophy or villous tip IELs (severe partial 
villous atrophy) strengthens the probability of CD in borderline cases where 
the histology is difficult to interpret  (Jarvinen TT 2003, Jarvinen TT 2004). 
 Ferguson introduced the terms of silent, latent and potential CD 
(Ferguson A 1993) indicating subjects with no symptoms, but severe 
mucosal damage (silent), and subjects with positive antibodies but a normal, 
or almost normal, jejunal mucosa (latent and potential), with latent being 
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different from potential patients, as the former had already shown, at least 
once in their life severe gluten-dependent villous atrophy. Thus, the 
potential CD is a patient has anti-endomysium antibodies (EMA) and/or 
anti-human tissue transglutaminase antibodies (TG2), the typical HLA-
predisposing genotype (DQ2 or DQ8), but a normal or minimally abnormal 
mucosa architecture (increased intraepithelial count) at the intestinal biopsy 
examination. Potential CD patients present a high count of intraepithelial 
lymphocytes and subtle pathological alteration such as increased density of 
intraepithelial lymphocytes expressing γδ TCR, signs of activated mucosal 
cell-mediated immunity (such as expression of CD25 and B7 by lamina 
propria mononuclear cells), coeliac-like intestinal antibody pattern, and 
positive rectal gluten challenge (Troncone R 1996, Paparo F 2005). Several 
studies investigated antibody pattern in small intestinal aspirate to 
characterize CD-associated markers, that could identify latent/potential CD 
patients. The coeliac-like antibody pattern in jejunal fluid was observed in 
patients with clinical symptoms of CD but with normal jejunal biopsy 
histology and some of these patients were clinically gluten sensitive (Arranz 
E 1993). Similarly patients with irritable bowel syndrome (IBS) had 
increased CD associated antibodies in duodenal aspirate and were HLA-
DQ2 positive. Interestingly, stool frequency and duodenal antibodies 
decreased significantly under a gluten-free diet in the subgroups of  HLA-
DQ2-positive and intestinal antibody-positive IBS patients (Wahnschaffe U 
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2001). In the recent study with the aim to identify a marker to detect coeliac 
disease before the development of villous atrophy, the authors demonstrate 
that intestinal transglutaminase autoantibodies deposits have a sensitivity 
and specificity of  93% in detecting subsequent coeliac disease (Salmi TT 
2006). 
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GUT IMMUNE SYSTEM 
In the gut is a delicate balance between the need to recognise pathogens 
and to prevent unwanted immune responses to food antigens or the normal 
intestinal flora, yet allowing adequate nutrient uptake at the same time. 
Considering the large area of the gastrointestinal tract, it is not surprising 
that it has developed both immunologic and non-immunologic ways of 
protection. The mucosa barrier consists of intestinal epithelial cells 
connected by tight junctions and non-immunologic defence mechanisms 
such as low pH, peristalsis, and mucus coat, all together protecting the 
intestine from invading antigens (Sanderson IR 1999).  
The intestinal lymphoid tissue is the largest compartment of the 
immune system in the body and referred to as the gut-associated lymphoid 
tissue (GALT). It consists of mesenteric lymph nodes, Peyer’s patches, 
isolated lymph follicles and large numbers of lymphocytes scattered 
throughout the lamina propria and epithelium of the intestine (MacDonald 
TT 2003).  
 
Human regulatory T cell analysis in the gut  
The immune system controls activation of the innate as well as the 
adaptive arms through various means, primarily including induction of 
anergy apoptosis of activated immune cell and the activities of regulatory 
CD4+ T cells. In addition, several other regulatory mechanism are 
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operational in the gut mucosa, including CD8+ T cells, γδ+ T cells and 
NKT cells, that are highly correlated with their surrounding epithelial cells, 
and IL 10 secreting B cells, immature dendritic cells and plasmacytoid 
dendritic cells.  
It is becoming increasingly clear that the most important among these 
regulatory cells reside within the CD4+ T cell population. These cells play 
an important role in induce and maintaining peripheral self-tolerance and 
thus preventing immune pathologies. Several types of regulatory T cell 
(Tregs) have been identified and the mechanisms of suppression may 
different. They can be divided into two major groups, the so-called 
“naturally occurring” regulatory T cells and “adaptive” regulatory T cells, 
that include Th3, Tr1 and CD8+ T cells (Fig. 2; Tab. 1).  
“Naturally occurring” regulatory T cells. Most CD4+ T cells that 
recognise autoantigens in the thymus with high affinity are either clonally 
deleted or differentiate into a “naturally occurring” Treg. The thymus-
derived naturally occuring CD4+ T cells comprise 1-2% of human 
peripheral CD4+ T cells and 5-10% of mouse (Fig. 2; Tab. 1). These cells 
are selected in the thymus and thus have a pre-defined antigen specificity 
(Sakaguchi S 2004, Shevach EM 2004). More recently, many groups have 
found that CD4+CD25+ Treg cells can also be induced in the periphery 
from naïve precursors (Walker MR 2003). Thymus derived Treg, initially, 
were identified by their CD4+CD25high phenotype but an increasing 
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number of markers has been recently reported. These cells also express 
intra-cytoplasmic and cell-surface CTLA-4 (CD152), which is a negative 
regulator of cell-mediated immunity, and GITR (Glucocorticoid-induced 
Tumor necrosis factor(TNF) receptor family-Related), which is a member 
of the TNF receptor superfamily. CD25, as well as CTLA-4 and GITR can 
also be observed on activated non-regulatory T cells, so these molecules 
does not functionally define the Treg cell. A significant advance in more 
precisely defining the Treg population occurred when the forkhesd 
trascription factor FOXP3 was identified as being necessary for Treg 
development. Mutations in the Foxp3 (murine)/ FOXP3 (human) gene were 
identified as the sole genetic defect underlying the phenotypes of the fatal 
autoimmune diseases of the scurfy mouse (Bruskow ME 2001) and human 
IPEX syndrome (immune dysregulation, polyendocrinopathy, enteropathy, 
X-linked syndrome) a rare monogenic disease of male children that is 
accompanied by autoimmune disease, such as type 1 diabetes, IBD, and 
severe allergy (Bennett CL 2001). The foxp3 gene was identified as a 
master regulatory gene; it is constitutively and specifically expressed in 
natural Treg and plays an indispensable role in their development and 
function. The specificity of foxp3 in mice is clear; it is solely expressed in 
Treg and the scurfy mutation is always related to defective suppressive 
function. Conversely, the expression of FOXP3 in humans is not restricted 
to Treg and can be induced on activation of conventional T cel, albeit at 
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much lower levels than in natural Treg. Recent research has demonstrated 
that CD127 expression is down-modulated on Treg cells (Liu W 2006). 
CD127 is part of the heterodimeric IL-7 receptor that is composed of the 
CD127 and the common γ chain, which is shared by other cytokine 
receptors ( IL2R, IL4R, IL9R, IL15R and IL21R). CD 127 is expressed on 
thymocytes, T and B cell progenitors, mature T cell, monocytes, and some 
other lymphoid and myeloid cells. Studies have shown that the CD127 
plays an important  role in the proliferation and differentiation of mature T 
cells, and in vitro experiments show that the expression of CD127 is down-
regulated following T cell activation. The correlation of down-regulated 
CD127 on T cells with high-to-intermediate expression of CD25 on Treg 
cells was confirmed by intracellular staining of Foxp3 antigen to identify 
Treg cell (Liu W 2006, Seddiki N 2006). 
Human Treg can be greatly expanded ex vivo by TCR stimulation in the 
presence of high concentrations of IL-2  and CD25 is functionally essential 
as a key component of the high affinity IL2 receptor. The exact mechanism 
of suppression by Treg remains uncertain.  In vitro studies has shown that 
the proliferation of the responder T cells and their cytokine production is 
strongly suppressed in the presence of Treg. The suppressive function is 
cell contact dependent and independent of cytokines (Earle KE 2005, 
Setoguchi R 2006). However, mouse studies have proven the suppression 
to be dependent on cytokines such as transforming growth factor (TGF)β 
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and IL10. The mechanisms responsible for these differences between in 
vivo and in vitro results remain to be fully explained.  
“Adaptive” regulatory T cells. Apart from the CD4+ CD25+ thymus 
derived Treg, other types of Treg cells that can develop in the periphery are 
the Tr1 and Th3 types of regulatory cells (Fig. 2; Tab. 1). T regulatory type 
1 cells are induced by an IL10–dependent process in vitro and in vivo. They 
are defined by their capacity to produce high levels of IL 10 and TGF β and 
IL5, low amounts of IFN γ and IL2 and no IL4. Several investigators have 
demonstrated that Tr1 cells do not constitutively express FOXP3 unlike of 
naturally occurring CD4+CD25+ Treg cells, but upon activation it can be 
up-regulated to levels similar to those observed in activated CD4+CD25- T 
cells (Vieira PL 2004, Levings MK 2005) Tr1 cells regulate immune 
responses through the secretion the immunosuppressive cytokines IL 10 
and TGF β, and they suppress both naïve and memory T cell responses in 
vivo and in vitro. Although Ag-specific Tr1 cells need to be activated via 
the TCR in order to exert their suppressive function, once activated, Tr1 
cells can mediate bystander suppressive activity against other Ags. This 
bystander suppression is likely mediated by the local release of IL10 and 
TGF β which act on both APC and T cells. IL10 down regulates expression 
of co-stimulatory molecules and pro-inflammatory cytokine production by 
APC and directly inhibits IL2 and TNF α production by CD4+ T cells 
(Groux H 2003, Pestka S 2004). Similarly, TGF β down-regulates the 
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function of APC and inhibits proliferation and cytokine production by T 
cells (Strobl H 1999, Cerwenka A 1999). The suppressive effects of Tr1 
cells are typically either partially or fully reversed by addition of anti-IL10 
and anti-TGF β neutralizing mAb, but additional mechanisms may also 
contribute. 
Th3 progenitor cells are similar to the Tr1 cells in that they are also 
CD4+CD25-Foxp3- (Fig. 2; Tab. 1). Th3 cells secrete mainly TGF-β and 
to a lesser extent IL4 and IL10 (Chen 1994, Fukaura 1996). 
IL10-secreting Tr1 or TGFβ-secreting Th3 cells, may also express 
Foxp3 (Levings MK 2002), suggesting that the T regulatory cells do not 
constitute separate lineages.  
CD8+ Tr1 like cells, with produce significant amounts of IL10, low 
IFNγ and no IL4, IL5 and nor TGFβ, have also been described (Fig. 2) 
(Gilliet M 2002, Steinbrink K 1999).CD8+ T regulatory cells are less well 
characterized and are reportedly capable of suppressing CD4+ cells in 
vitro. This conclusion is based upon inhibition of proliferation of CD4 T 
cell during the stimulation of CD8+ T regulatory cells with anti CD3 
antibodies. In this case, the regulation involves a cell-cell contact-
dependant mechanism. These cells also display the commonly accepted 
markers for Treg cells; CD25 and Foxp3, the latter of which is induced 
upon anti-CD3 stimulation (Bisikirska B 2005).  
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  Fig. 2  Regulatory T cells and their function. Several types of regulatory T cells have 
been identified and the mechanisms of suppression may differ. Thymus derived regulatory 
T cells, also known as naturally occurring regulatory T cells, are a subset of CD4+CD25+ 
T cells and are thought to suppress activation of T cells at level of antigen presenting cell. 
Adaptive peripheral induced regulatory T cells include Tr1, Th3 and CD8. These cells 
produce the immunosuppressive cytokines IL10 and TGFβ and function in a cytokine 
dependent manner (Huibregtse IL 2007).  
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Cytokines  
An immune response to an invading pathogen is an essential 
mechanism to provide specific defence against any particular antigen. 
Regulation of the magnitude and duration of this response is essential to 
prevent hypersensitivity and/or autoimmune reactions. This 
immunoregulation is controlled by soluble factors which perform the 
functions of the immune response and mediate signalling between the 
various cells involved. Such families of regulatory molecules include the 
cytokines and their antagonists, immunoglobulins, serum proteins, 
complement and other inflammatory mediators. 
Cytokines are a family of low molecular weight protein regulatory 
molecules involved in cell growth, inflammation, immunity, differentiation 
and repair. They are characterized by their pleiotropic activity, acting on a 
wide range of cell types, and, unlike hormones which are carried by the 
bloodstream throughout the body, cytokines generally act in a local manner 
through autocrine and paracrine mechanisms. Cytokines mediate their 
effects through binding to their receptors, which activates intracellular 
signals (Ho IC 2002). Any cytokine may have many different biological 
effects depending on the target cell, and different cytokines may have 
similar effects. Cytokines are not generally produced constitutively by 
cells, and once activated are tightly regulated. It is now accepted that T 
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helper (Th) lymphocytes, which are required for both cell-mediated and 
humoral immune response, are composed of two distinct subsets, Th1 and 
Th2, distinguished by different patterns of cytokines production (Mosmann 
TR et al 1986), and the type of response they elicit in target cells 
expressing cytokine-specific receptors (Kim J 1985). Th1 cells support 
CD8+ cytotoxic cells by production of IL2, macrophage activation and 
MCH class II expression by production of Interferon (IFN)-γ. They also 
support delayed type hypersensitivity (DTH) response, and 
immunoglobulin switching to IgG2a, and produce tumor necrosis factor 
(TNF)-β. The Th2 cells secretory pattern is characterized by IL4, IL5, IL6, 
IL10 and IL13 cytokines; they also contribute to B-cell activation, 
switching to the IG1 (in rat but not in humans), IgA and IgE isotypes and to 
antibody production. Th0 subset, postulated to be either precursors of Th1 
and Th2 cells or itself a final differential phenotype, is characterized by 
production of cytokines of both Th1 and Th2 types (Mosmann TR et al 
1986, De Carli M 1994). The dose of the antigen, strength of the signal 
through the TCR, and costimulation all influence on the Th differentiation, 
but the most potent determinant is the cytokine milieu itself around the cell, 
in particular IL 12 drives differentiation toward a Th1 and IL4 toward Th2 
(Ho IC 2002). Although a distinct Th1/Th2 cytokine profile is not as clear 
in humans as in animal cells, an inverse relation remains between the 
tendency of T cells to produce IFNγ as opposed to IL4 and IL5 
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(MacDonald TT 2001).  
Although CD4 T helper cells are the major sources of IL2, IFNγ and 
IL4, IL13, respectively, other cell types are able to produce these cytokines. 
Subsets of γ/δ cells and CD8+ cells can secrete Th1 or Th2 like cytokines 
pattern. NK cells produce IFNγ and  TGFα and contribute to the Th1 like 
response. IL4 is syntetized by macrophages, keratinocytes and B cells  
(Mosmann TR 1996). Cytokines are usually divided into 
proinflammatory(IL1, IL2, IL6, IL12, IL18, IFNγ and TNFα), anti-
inflammatory (IL4 and IL13) and immunosuppressive (IL10 and TGFβ), 
based on their activity.  
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PATHOGENESIS OF THE COELIAC DISEASE 
CD results from the interaction between gluten and immune, genetic, 
and environmental factors. CD is induced by the ingestion of gluten, which 
activates immune responses in the small intestine that lead to the 
destruction of the epithelial mucosa and subsequently cause deleterious 
effects on intestinal absorption of nutrients. For a long time it was thought 
that only the adaptive immunity plays a role in CD. It is now clear that both 
the adaptive and the innate immune responses are important in CD and that 
some gluten peptides seem to be involved in either one of these responses. 
This is also reflected by several gluten peptides having distinct pathological 
mechanisms in CD (Jabri B 2005). 
 
The role of gluten 
Gluten is derived from wheat, barley and rye. From a nutritional 
standpoint, it is a rather poor nutrient that provides elasticity and viscosity 
to food (Wieser H 1996). The term “gluten” refers to entire protein 
component of wheat; it is a mixture of gliadin and glutenin proteins. The 
gliadin is the alcohol-soluble fraction of gluten, it is a complex mixture of 
40 highly homologue proteins that are divided according to their 
electrophoresis mobility into 3 families: α/β-, γ- and ω-gliadins (Wieser H 
1996); the glutenins consist of low molecular weight (LMW)- and high 
molecular weight (HMW)-glutenins. A large numbers of studies have 
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shown that both gliadin and glutenins contain numerous immunogenic 
peptides (Kagnoff MF 2007).  
Gluten and related proteins are also known as prolamins for the high 
content of amino acids such as glutamine (Q)(40%) and proline (P)(20%). 
The high proline content renders these proteins resistant to complete 
proteolytic digestion by gastric, pancreatic, and brush border enzymes in 
the human intestine, since those enzymes are deficient in prolyl 
endopeptidase activity (Shan L 2005). Thus, relatively large peptide 
fragments with a high proline and glutamine content remain in the 
intestinal lumen after gluten ingestion (Shan L 2002). Nonetheless, the 
relatively poor digestion of these proteins alone is not sufficient to cause 
CD; there is no known difference between healthy individuals and those 
susceptible to developing CD in their ability to digest these proteins. The 
decrease in gluten digestion by brush border enzymes (propyl 
endopeptidase (PREP) and pyroglutamyl-peptidase I (PGPEPI)), observed 
in untreated CD patients when compared to controls seems to be secondary 
to impaired structure of the intestine and not causal. In fact, the two genes 
that encode for peptidase enzymes are also located in CD linkage regions 
(6q21-22 and MYO9B) and have been studied for their potential causal role 
in CD, but no association could be found (Monsuur AJ 2006). 
Experimental evidence has also indicated a direct, non immune-
mediated, cellular toxicity of gliadin-derived peptides in vitro on both cell 
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culture systems and mucosal explants. For example, a peptic-tryptic digest 
of gliadin (PT-gliadin) can agglutinate in vitro the K562 (subclone S) cell 
line and can interfere with the differentiation of fetal rat intestine, in 
addition to being capable of direct damage for the intestinal mucosa 
(Gianfrani C 2008). Furthermore, in cultures of coeliac small intestinal 
mucosa tissue (an in vitro model for the study of CD) the presence of PT-
gliadin or the short peptide 31-43 can specifically prevent a restitution of 
enterocyte height that would normally occur within 24-48 hours (De Ritis 
G 1988). Finally, PT-gliadin and the 31-43 peptide exert a direct cytotoxic 
effect on epithelial Caco2 cells through the induction of fas-mediated 
apoptosis and a delayed inactivation of the EGF receptor, phenomena that 
favour cell growth in the crypts of the atrophic mucosa of CD patients 
(Barone M 2007, Giovannini C 2000). 
 
Permeability of the epithelial barrier in CD 
The activation of immune response in the gut implies that gliadin 
and/or its breakdown peptides in someway cross the intestinal epithelial 
barrier and reach the lamina propria of the intestinal mucosa where they are 
recognised by antigen presenting cells (APCs). Despite the progress made 
in understanding the immunological aspects of the pathogenesis of CD, the 
early steps that allow gliadin to cross the intestinal barrier are still largely 
unknown. Under physiological circumstances the intestinal epithelial 
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barrier is described as being almost impermeable to macromolecules. 
During such healthy states, quantitatively small but immunologically 
significant fractions of antigens cross the defence barrier. These antigens 
are absorbed across the mucosa along two functional pathways. The vast 
majority of absorbed proteins (up to 90%) cross the intestinal barrier 
through the transcellular pathway, followed by lysosomal degradation  that 
converts proteins into smaller non-immunogenic peptides. The remaining 
portion of proteins is transported as intact molecules, resulting in antigen 
specific immune responses. This latter phenomenon utilises the paracellular 
pathway that involves subtle but sophisticated regulation of intercellular 
tight junction (tj) that can contribute to antigen oral tolerance (Fasano A 
1998). When the integrity of the tj system is compromised (such as during 
prematurity or exposure to radiation, chemotherapy and toxins) an immune 
response to environmental antigens, including autoimmune diseases and 
food allergies, may develop (Fasano A 2001). A important modulator of tj 
permeability is zonulin. Zonulin has a molecular weight of 47 kDa, an N 
terminal receptor binding motif that is structurally and functionally similar 
to the zonula occludens toxin (Zot) elaborated by Vibrio cholerae, and a C 
terminal domain probably involved in the rearrangement of cytoskeletal 
elements functionally connected to intercellular tj (Fasano A 2001). 
Following binding to its surface receptor, zonulin induces a protein kinase 
C (PKC) mediated polymerisation of intracellular actin filaments which are 
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directly connected to structural proteins of the tj (Fig. 3). The complex 
actin cytoskeleton network of the enterocyte is known to be involved in the 
intracellular trafficking of molecules as well as in the regulation of 
paracellular permeability by its direct interaction with the tj structural 
protein (Wang W 2000).  
In CD the intestinal permeability is increased in untreated CD patients 
but still present in treated patients and healthy relatives (Schulzke JD 1995, 
Uil JJ 1996). Increased permeability can be observed even in patients with 
dermatitis herpetiformis (DH) and no evidence of histological damage in 
biopsy specimens (Smecuol E 2005).  
In particular, in acute CD the crypt tj showed aberrant morphology, and 
in asymptomatic patients treated with the gluten-free diet, jejunal tj 
structure only partially recovered (Schulzke JD 1998). This could be 
mediated by zonulin, in fact recently it is demonstrated that zonulin 
expression is chronically up-regulated in CD gut tissues (Fasano A 2000, 
Smecuol E 2005).  
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 Fig. 3 Proposed zonulin/zonula occludens toxin (Zot) intracellular signalling leading to the 
opening of intestinal tight junctions. Zonulin and Zot interact with the same specific surface 
receptor (1) whose distribution within the intestine varies. The proteins are then internalised and 
activate phospholipase C (2) that hydrolyses phosphatidyl inositol (3) to release inositol 1,4,5-
tris phosphate (PPI-3) and diacylglycerol (DAG) (4). Protein kinase C (PKC) is then activated 
(5), either directly (via DAG) (4) or through release of intracellular Ca++    (via PPI-3) (4a). PKC 
catalyses the phosphorylation of target proteins with subsequent polymerisation of soluble G-
actin to F-actin (7). This polymerisation causes the rearrangement of the filaments of actin and 
the subsequent displacement of protein (including ZO-1) from the junctional complex (Fasano 
A 2001).                
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The adaptive immune response 
The adaptive immune response involves gliadin-reactive CD4+ T cells 
in the lamina propria that recognize gliadin peptides, which are bound to 
HLA class II molecules DQ2 or DQ8 on antigen-presenting cells (APCs). 
Gluten-specific CD4+ T lymphocytes can be isolated from small intestinal 
biopsies of CD patients but not from controls (Sollid LM 2005).  
How HLA-DQ2 and HLA-DQ8 bind such peptides was an enigma for 
several years, because the peptide-binding groove of HLA-DQ2 and DQ8 
favors the binding of peptides with negatively charged residues at key 
anchor positions. Such negatively charged amino acids are largely absent 
from native “gluten” peptides generated in the human intestinal tract. 
However, this puzzle was solved after the discovery that the target antigen 
of an autoantibody present in many CD patients was a calcium-dependent 
tissue transglutaminase (TG2). Tissue TG2, witch is released in the 
intestinal mucosa during tissue injury, has a role in tissue repair and cross-
links proteins by forming isopeptide bonds between glutamine and lysine 
residues. In fact, the most important function of TG2 is to catalyze post-
traslational modification of proteins by transamidation or deamidation. In 
particular, deamidation occurs in the absence of suitable amines involves 
water and occurs at lower pH. It results in the transformation of neutral 
glutamine into negatively charged glutamic acid. Gliadin is an excellent 
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TG2 substrate because of its high glutamine and proline content (Molberg 
O 1998). Thus, deamidation plays an important role in favoring the binding 
of gliadin peptides to DQ2 or DQ8 molecules, which possess binding 
pockets that have a preference for negatively charged amino acid residues. 
Only particular glutamine residues, however, are modified by TG2. Vader 
LW and colleagues (Vader LW 2002) have shown that the spacing between 
glutamines and proline determines which glutamines in gluten will be 
modified in the process of deamidation. Several distinct gluten T cell 
epitopes exist and they have been found in α-gliadins, γ-gliadins and, 
recently, in ω-gliadins (Gianfrani C 2008). A single 33-mer peptide has the 
highest T-cell stimulatory capacity in a large cohort of CD patients. This 
peptide maps at the level of the 56-88 residues of α-gliadin and harbors six 
copies of three different T-cell epitopes (Shan L 2002). This 33-mer 
fragment is rich in proline; proline affects gluten immunogenicity by 
inferring resistance to gut proteolysis, by its importance for TG2 specificity 
and by dictating binding of the peptides to the HLA molecules. 
Nonetheless, HLA-DQ2-restricted T cells from children with CD recognize 
also “gluten” peptide that do not contain deamidated glutamine residues; 
this indicates that glutamine deamidation is not required for the initiation of 
an anti-gliadin immune response (Vader W 2002). Perhaps, deamidation 
plays a role, not in allowing an anti-gluten response to take place but 
altering the nature of the anti-gliadin response. So, deamidation may 
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reshape the anti-gliadin response by favoring the binding to DQ molecules 
and by amplifying the immune response (Jabri B 2005) (Fig. 4).  
In addition to deamidation, TG2 can also cross-link glutamine residues 
of peptides to lysine residues in other proteins, including itself. It is 
possible that complexes between gluten and TG2 permit gluten reactive T 
cells to provide help to TG2 specific B cells enabling them switch their 
antibody production from IgM to IgA or IgG by a mechanism of 
intramolecular help (Sollid LM 1997). There are several studies which have 
addressed whether the anti-TG2 antibodies are involved in development of 
the coeliac lesion in the gut. Deposition of TG2 antibodies to extracellular 
fibrinogen bound TG2 is an early sign in development of CD, and this can 
be seen with the sign of overt pathology in the gut (Salmi TT 2006). The 
antibodies have weak inhibitory effect on the transamidating activity of 
TG2 in vitro, but this inhibitory effect is probably insufficient to affect the 
in vivo enzymatic function of TG2 (Esposito C 2002; Dieterich W 2003). 
Serum IgA of CD patients have been found to inhibit epithelial cell 
differentiation in a co-culture model of fibroblasts and epithelial cells 
(Halttunen T 1999). These are interesting lead observations, but further 
knowledge is necessary to conclude whether the anti TG2 antibodies are 
involved in the immunopathogenesis of CD.  
Upon their activation, the gluten reactive T cells produce cytokines of 
which IFNγ is clearly dominating. Paradoxically, the major Th1 inducing 
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cytokine, IL12, has not been detected in the CD mucosa (Nilsen 1995, 
Nilesen 1998). IL18 (Salvati VM 2002) and IFNα (Monteleone G 2001) 
are both candidate as driving factors for Th1 differentiation and IFNγ 
production. An increased mRNA expression of IL6, IL1β, TNFα, IL2 and 
TNFβ was found in the small intestinal mucosa of untreated CD patients, 
whereas no differences in IL4 production was observed. There were results 
discordant for expression of IL10 and TGFβ (Lahat N 1999, Kontakou M 
1995,  Beckett CG 1996, Lionetti 1999, Salvati VM 1999). 
The signalling pathway related to gamma interferon has also been 
explored: persistent STAT1 activation was observed (Mazzarella G 2003) 
as well as enhanced interferon regulations factor 1 (IRF1) expression 
(Salvati VM 2003). IL10 is also increased, but not enough to control the 
strong gamma IFN production (Forsberg G 2002). Downstream T cell 
activation,  a complex remodelling of the mucosa takes place, involving 
increased levels of metalloproteinases (Daum S 1999) and growth factors 
(Salvati VM 2001) which leads to the classical flat mucosa. 
 
The innate immune response  
It is clear that the activation of CD4+ T cells is not sufficient to explain 
the destruction of surface epithelial cells, the dramatic increase in IELs, and 
their malignant transformation. All these characteristic features of CD are 
not found in other intestinal diseases, such as Crohn’s disease and 
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autoimmune enteropathies, that are associated with CD4+ T cell activation 
and high levels of IFNγ expression in the lamina propria. Recent studies 
suggest that activation of the innate immune system is important in the 
pathogenesis of CD and in some of the complications of this disease, 
namely in refractory CD and in development of enteropathy-associated T 
cell lymphomas (EATLs).  In particular, an increase in the number of IELs 
in the mucosa of the small intestine is a characteristic feature of CD, and 
these cells are likely to be important for the ongoing pathogenesis of CD 
(Jabri B 2000). Following activation, IELs from patients with CD change 
from being typical antigen-specific T cells to being NK-like cells able to 
mediate epithelial damage through the recognition of stress-induced 
molecules on intestinal epithelial cells (Meresse B 2006). IELs, in fact, 
expressing the T cell receptor (TCR) and CD8 can also express NK cell 
receptors (NKRs) like NKG2D, CD94/NKG2A and CD94/NKG2C. The 
cytokine IL15 takes center stage in this process. Gluten induces epithelial 
cell stress that results in the up-regulation of IL15 and non-classical MHC 
class I molecules. In particular, IL15 induces increased expression on 
intestinal epithelial cells of epithelial cell surface ligands, such as MIC 
(ligand for NKG2D), while HLA-E (ligand for CD94/NKG2A and 
CD94/NKG2C) can be induced by IFNγ. These molecules up-regulate the 
activating NKRs of epithelial effector cytotoxic T cells leading to reduce 
the TCR activation threshold and mediate direct killing of epithelial cells 
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expressing the appropriate non-classical MCH class I ligands (MIC and 
HLA-E) (Jabri B 2007). Thus, the reduction of the TCR activation 
threshold and the arming of NKRs to mediate direct killing in IELs can 
explain how IELs can kill epithelial cells without recognizing gliadin 
peptides. Activation of intraepithelial lymphocytes is likely to contribute to 
epithelial cell apoptosis and villous atrophy via FAS/FAS ligand (Maiuri L 
2001) and perforin-granzyme (Ciccocioppo R 2000) pathways.  Because 
arming of NKRs by IL15 to kill in an antigen non-specific manner can only 
occur in effector T cells, the questions of what is the initial TCR trigger of 
IEL activation and whether this trigger is specific to coeliac disease are 
raised (Fig. 4).   
Several studies have reported that gluten can induce a stress response in 
epithelial cells and these effects have also been linked with effects of 
gluten on innate immune cells like macrophages and dendritic cells (DCs) 
(Maiuri L 2003). Peptides in the amino-terminus of α-gliadin (p31-49 and 
p31-43) are a prototype gluten fragment which may exert such effects. 
Independently  by binding to HLA-DQ2 or HLA-DQ8, they are able to up-
regulate IL15 production by intestinal epithelial cells, to increase IEL 
infiltration and epithelial cells apoptosis in human intestinal mucosa organ 
culture model, and to cause epithelial damage when instilled into the 
human duodenum (Hue S 2004, Maiuri L 2003). This findings raise another 
question: why does “gluten” not induce similar responses and epithelial cell 
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damage in everyone’s small intestine? Notwithstanding their auto-
reactivity, the intraepithelial T cells with NKRs seem to be under the 
control of gluten reactive CD4 positive cells. This argument is based on the 
observation that HLA is a necessary genetic factor for the development of 
CD. Still the mechanism for this crosstalk between the gluten reactive 
CD4+ T in the lamina propria and intraepithelial CD8+ T cells expressing 
NKRs is currently unknown. However,  neo-expression of the NKR ligand 
HLA-E by epithelial cells as a function of CD4 T cell produced IFNγ offers 
an attractive possibility. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 (a) the parts of the gluten proteins that are resistant to processing by luminal and brush 
border enzymes survive digestion and are transported across the epithelial barrier as 
polypeptides. Gluten peptides are deamidated by TG2. CD4+ T cells in the lamina propria 
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recognize predominantly deamidated gluten peptides, presented by HLA-DQ2 or DQ8 
molecules on the cell surface of APC. In the epithelium there is infiltration of CD8+ T cells that 
express NK cell receptors (NKRs), such as NKG2D. in the lamina propria there are B cells 
specific for gluten and TG2. (b) Intraepithelial T cells, by up-regulation of NKG2D, can kill 
enterocytes expressing MIC molecules either by reducing the TCR activation threshold or by 
mediating  direct killing. Gluten can induce NKG2D and MIC expression by stimulating the 
expression of IL15. (c) Hla-DQ2 and DQ8 molecules have a preference for binding peptides 
with negatively charged amino acids and thereby bind gluten peptides deamidated by TG2 with 
increased affinities. (d) a model of how gluten-reactive T cells control the formation of 
antibodies to TG2 by intramolecular help. This can happen in the lamina propria or, more likely, 
in the mesenteric lymph nodes. The complexes are endocytosed and degraded in endosomes 
where gluten peptides are released for binding to DQ2 or DQ8 molecules. After transport of 
DQ2/DQ( with bound peptides to the cell surface, gluten-reactive T cells can recognize the 
gluten peptides and threby provide T cell help to the TG2-specific B cell. (Sollid LM 2005). 
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 RESEARCH PROJECT 
This thesis reports the results I obtained during the Doctorate in 
“Human Reproduction, Development and Growth “ (XXI Cycle) from 
2005-2008. During the past 3 years, my research has been focused in the 
clinical and molecular characterization of CD and in particular of potential 
CD. 
In particular the following lines were developed: 
1. The coeliac disease diagnostic criteria. 
2. Spectrum of coeliac disease: “potential” coeliac disease. 
3. Immunologic markers in potential coeliac disease: cytokines and T 
regulatory cells. 
4. Immunologic markers in coeliac patients with selective IgA 
deficiency. 
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1.  THE COELIAC DISEASE DIAGNOSTIC CRITERIA 
The first objective of my research project was to investigate the 
diagnostic methods used by Italian pediatricians in their diagnostic 
approaches to CD.  
In 1990, current criteria followed for the diagnosis of CD were 
introduced by the members of European Society of Paediatric 
Gastroenterology, Hepatology and Nutrition (ESPGHAN) (Working Group 
of  ESPGAN 1990). These criteria are based on two main requirements: the 
finding of villous atrophy with hyperplasia of the crypts and abnormal 
surface epithelium, while the patient is eating adequate amounts of gluten; 
and a full clinical remission after withdrawal of gluten from the diet. The 
finding of circulating IgA antibodies to gliadin, reticulin, and endomysium 
at the time of diagnosis, and their disappearance on a gluten-free diet, adds 
weight to the diagnosis (Working Group of ESPGAN 1990).  
Since the introduction of the revised ESPGAN criteria in 1990, 
serological methods have greatly improved with the introduction of anti-
tissue TG2 antibodies measurement (Troncone R 1999). Similarly HLA 
typing has been increasingly used in clinical practice (Sacchetti L 2001). At 
the same time, the awareness of different clinical manifestations of coeliac 
disease has evolved, as well as the recognition of a wide spectrum of 
histological alterations.  
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In a situation where jejunal histology has lost specificity, and with the 
growing contribution by serology, and to a less extent by HLA, I believe, in 
according with many, that the current diagnostic criteria for CD need a 
revision. Starting from this supposition, this study was designed in order to 
create the basis for a possible revision of the 1990 ESPGHAN guidelines.   
In this study a nationwide questionnaire on current diagnostic routines 
was sent by mail to 54 Italian centres for CD diagnosis. The questionnaire 
contained 12 multiple choice questions, divided in three sections: the first 
section regarded the serological tests used in the centres, the HLA typing 
and immunohistochemistry, if performed; the second section was focused 
on the diagnostic criteria currently used in symptomatic and asymptomatic 
children; the third section concerned the clinical management in some 
special cases, such as children below the age of 2 years, children with 
positive serology and normal mucosal architecture (potential CD), and IgA 
deficient patients. 
The results of this study, reported in detail in the following enclosed 
paper, provided that in all the centres anti-TG2 measurement is routinely 
performed, followed by EMA to confirm the results. In a smaller number of 
cases, an AGA antibody measurements is still used. 87.5% of the centers 
perform HLA typing. In most cases the test is used to ascertain 
susceptibility to develop the disease, especially in high risk patients, such 
as first degree relatives, but it is also used in unclear cases mainly to 
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exclude the possibility of CD. Up to 67.5% of centres consider an 
infiltrative lesion (Marsh 1) consistent with CD diagnosis; interestingly, 
15% will make a diagnosis of CD even with completely normal mucosa, if 
patients are symptomatic and have a positive serological analysis. In 
dubious cases, 80% of centers perform immunohistochemical analysis; but 
only 5% analyze γδ+ intraepithelial lymphocytes. The gluten challenge is 
performed in children younger than 2 years in only 20% of the Centers and 
more than 80% do not perform a second biopsy to verify the effects of a 
gluten-free diet in clinically silent patients, as recommended by the 1990 
criteria.  
Despite the new diagnostic tools available, ESPGHAN criteria are still 
widely followed by Italian diagnostic Centers; the only exception regards 
the gluten challenge, which is not performed in children younger than 2 
years and in clinically silent patients, as recommended by the 1990 criteria.  
The question if the intestinal biopsy is or not necessary remain still open. 
It is well-established that increased EMA and TG2 in both children and 
adults correlate with abnormal small bowel histopathology (Tursi A 2003, 
Donaldson MR 2007). Thus, the patients with high titers of anti-TG2 
antibodies, HLA DQ2 or DQ8 positivity and gluten-dependent symptoms 
almost invariably have a villous atrophy (Green PH 2003); in these cases 
diagnosis could probably be established without small bowel biopsy 
(Kaukinen K 2001). But, it is now clear that CD encompasses a large 
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spectrum of clinical manifestations that range from serious symptomatic 
forms to completely asymptomatic forms. At the same time, from a 
histological point of view, it goes from the typical severe lesions of 
duodenal mucosa to forms characterized by minor degrees of enteropathy 
(Marsh MN 1992).  
The patients with minor degrees of enteropathy (potential or early-
developing CD) do not fulfill the traditional ESPGHAN diagnostic criteria. 
In these case, the contribution of the analysis of jejunal biopsies may still 
be very important to define the disease state. In particular, when CD is 
suspected, but histology is not diagnostic increased density of γδ 
lymphocytes (Spencer J 1991) and villous tip IEL (Jarvinen TT 2004) 
supports the diagnosis of CD. Few centers, however, are able to perform 
such an analysis since it requires frozen biopsies.  
In conclusion, until serological methods are improved,  the  genetic 
make up of coeliac patients is better defined, it seems wise for a diagnosis 
of coeliac disease still  rely on a combined approach based of clinical 
criteria,  histology, serology and genetics. Moreover, a revision of the 
current ESPGHAN criteria might be useful, as has already been frequently 
suggested, but it should be evidence-based. Large, multicenter studies are 
greatly needed. 
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2. SPECTRUM OF COELIAC DISEASE: “POTENTIAL” COELIAC 
DISEASE. 
The second line of my research had the aim of elucidation of natural 
history of children with serum positive CD-related antibodies and 
architecturally normal small intestinal mucosa. 
 
Introduction  
In the last decade, it has become increasingly evident that CD is not 
restricted to severe gluten-dependent enteropathy. From an histological 
point of view, in fact,  CD represents a spectrum that goes from the typical 
severe lesions of duodenal mucosa, such as villous atrophy, to forms with a 
normal architecture of duodenal mucosa and only an increased infiltration 
of the intraephitelial lymphocytes (IELs) (Marsh MN 1992). In clinical 
practice, by increased diagnostic efficiency of serum CD-related 
autoantibodies measurements and increased attention for CD than in the 
past, it is increasingly more common to find patients who have serum 
positivity for CD autoantibodies but whose duodenal mucosa shows a 
normal histological appearance. The potential CD is a patient with anti-
endomysium antibodies (EMA) and/or anti-human tissue transglutaminase 
antibodies (anti-TG2) in serum, but a normal  mucosal architecture at the 
intestinal biopsy examination. Good markers of potential CD include subtle 
pathological alteration such as increased density of intraepithelial 
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lymphocytes expressing γδ TCR, signs of activated mucosal cell-mediated 
immunity (such as expression of CD25 and B7 by lamina propria 
mononuclear cells), coeliac-like intestinal antibody pattern. Recent work 
have demonstrated that first-degree relatives of coeliac patients presents a 
positive rectal gluten challenge (Troncone R 1996, Paparo F 2005). 
Clinical, histological and serological markers predictive of atrophy 
developing are not known. 
The IELs are increased in the mucosa of untreated coeliac patients, but 
these cells are not pathognomic for CD. Certainly, an increase of δγ + IELs 
(Jarvinen TT 2003) or the count of intraepithelial lymphocytes at the 
villous tip  (Jarvinen TT 2004) strengthens the probability of CD in 
borderline cases where the histology is difficult to interpret. Finally, in a 
recent study with the aim to identify a marker to detect coeliac disease 
before the development of villous atrophy, the authors demonstrate that 
these deposits would have the best sensitivity and specificity to predict the 
evolution to overt CD (Salmi TT 2006).  
The clinical spectrum of potential CD, like the classical coeliac disease, 
is wide. The patients with serum CD-related antibodies and intact duodenal 
villi can present at diagnosis intestinal complaints, such as abdominal pain, 
diarrhoea, nausea, vomiting, and bloating or have extraintestinal symptoms 
or be silent, as described in a recent study (Dickey W 2005). Dickey W et 
al report a incidence of potential CD of 10% in adult population: the 34% 
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of potential CD patients were first-degree relatives and the 17% were 
affected by autoimmune disease.  
The only accepted treatment for CD is a strict adherence to gluten-free 
diet (GFD), on which histology and symptoms should normalize (Walker-
Smith JA 1990). There are no clear guidelines as to how best to deal with 
potential CD subjects, and in particularly whether a life-long gluten free 
diet (GFD) is necessary in subgroup of asymptomatic patients with normal 
intestinal mucosa and serum CD-associated antibodies. It is quite clear that 
subjects with severe gluten dependent enteropathy face a series of health 
risks, mainly nutritional; they probably have also higher risk of developing 
autoimmunity,  and, although less than previously thought, of presenting 
neoplastic complications. On the contrary, little is known of those with 
minor enteropathy. A recent report (Kaukinen K 2001) showed nutritional 
deficiencies also in patients with minor enteropathy, positive serology and 
“risk” genetics, resolving on a gluten free diet.  
Starting from consideration that more information is also needed on the 
natural history of patients with minor inflammation, in particular on 
features influencing the degree of gluten-dependent inflammation, on the 
markers predictive of evolution to frank CD and on the health risks they are 
exposed to, if left on a normal gluten-containing diet, the objective of my 
research was the characterization of clinical, biological and histological 
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features of children with positive CD-associated serum antibodies and 
architecturally normal small intestinal mucosa by longitudinal evaluation.   
 
Patients 
At this propose our study involved 80 children (24 male and 56 female 
with a median age of  6 years and 8 month; range 18 months-16 years and 2 
months), who underwent small intestinal biopsy for the suspicion of CD in 
the Department of Pediatrics in Naples University Hospital “Federico II” 
Italy from January 2000 to December 2007. They were selected according 
to the presence in their serum of EMA and/or  a value of anti-TG2 
antibodies higher than cut-off and architecturally normal small intestinal 
mucosa (Marsh 0 and Marsh 1). We have excluded patients with IgA 
deficiency.  
These potential CD patients were strictly followed-up every sex months 
with: clinical evaluation (symptoms evolution, growth parameters, amount 
of daily gluten intake,) laboratory evaluation (CD-related autoantibodies, 
thyroid autoantibodies, nutritional parameters, organ functionality, bowel 
inflammatory indexes). A jejunal biopsy was performed again every two 
years of follow-up in patients with persistent positivity for EMA and/or 
anti-TG2; before, only in case of symptoms development.  
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Results  
Patients with potential coeliac disease represented the 14.1% (194/1373) 
of the patients with diagnosis of coeliac disease in the considered period.  
Patients characteristics 
35/80 patients belonged to “at risk group”;  22 were first-degree relatives 
of coeliac patients and 13 presented other autoimmune diseases: 11 were 
diabetics patients and 2 had a thyroiditis. Most of them (43/80 53.7%) were 
asymptomatic while 37/80 presented symptoms, in particular 33 
gastrointestinal symptoms (e.i. recurrent abdominal pain, weight loss, 
recurrent diarrhea, failure to thrive); and 4 extraintestinal symptoms (e.i. 
short stature, iron deficiency anemia). The decision of beginning a GFD 
was based no symptoms severity.  
Patients that began a GFD 
16/80 patients began a gluten free-diet because of symptoms or signs 
suggestive of CD: 2 for short stature with no other causes; 2 for 
pathological value of Z-score at BMD; 3 for failure to thrive; 5 for recurrent 
abdominal pain; 2 for diarrhoea; 1 for thyroditis and dilatative 
cardiomyopathy. In 1 case the parents refused to start GFD: the indication 
was due to a pathological value of Z-score at BMD. 6/15 didn’t show any 
response to GFD: 2 continued to have the same stature percentile of the 
beginning after more than 2 years of diet, 2 continued to present a failure to 
thrive after 1 year of diet and in 2 cases the recurrent abdominal pain 
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persisted. In 3/6 cases, for the absence of response, the patients started 
again a gluten containing diet  and repeated a second biopsy that resulted 
normal. In the 2 cases in which the diet was begun for a pathological value 
of Z-score at BMD we have not repeat the exam yet because less than 2 
years  have passed. All patients on a GFD  presented  negativization of CD-
related serology as any other coeliac patient with atrophy (Tab. 1).  
Patients that continued a gluten containing diet 
The 64/80 patients that continued a gluten containing diet and the 3/15 
that started a gluten containing diet again underwent a strictly follow-up 
every-six months. All the asymptomatic patients continued to be 
asymptomatic while in 11 cases symptoms presented at the moment of the 
diagnosis disappeared during the follow-up (Tab.1).  
Autoimmune diseases 
Of the 67 patients that continued a gluten free diet 1/67 developed a type 
1 Diabetes few months after the first biopsy and 3/67 developed a 
thyroiditis, in 1/3 the patients became negative for CD-related antibodies 
before the developing of the thyroiditis. 
Dietary assessment 
At the moment of the first biopsy the daily gluten intake of patients with 
potential CD had a media of 15 grams with a range from 6 to 40 g/die. 
These values were equivalent to those of control group. Even the calcium 
quantities were similar to those of the control group.  
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HLA typing 
In 67/80 HLA typization was performed. 66/67  patients presented an 
HLA consistent with CD with a positivity of DQ2 and/or DQ8: 46/67 were 
positive for HLA A1*0501 B1*0201—two haplotype either in cis or in 
trans, and 10/67 for the HLAB1*0302 haplotype; 5/67 patients presented a 
positivity for HLA A1*0501 B1*0201 and HLAB1*0302, while only 5/67 
presented a positivity only for HLA A1*0501 or HLA B1*0201. Only 1 
patients was negative for all the HLA haplotypes associated with CD, his 
HLA was DQB1*05/DQB1*06. 
Serology 
At the moment of the first biopsy 64/80 patients were positive for both 
EMA and anti-TG2, 14/80 patients only for EMA and 2/80 patients only for 
anti-TG2. Anti-TG2 titres were significantly lower than those of coeliac 
patients with atrophy as already demonstrated in a previous work  (Paparo F 
2005). 
During the follow-up 32/67 patients that continued a gluten containing 
diet had a persistently positive serology with EMA positivity and values of 
anti-TG2  higher than cut-off, in 5/67 cases the serology became completely 
and persistently negative both for EMA and anti-TG2 while  30/67 showed 
a fluctuation of antibodies titres with transient negativity for EMA or anti-
TG2 values. The fluctuation and negativization were more frequent in those 
who at the beginning presented lower titres of anti-TG2. 
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Nutritional Parameters 
3/67 presented hypoferritinemia that solved with iron therapy, other 
nutritional parameters and coagulation parameters were normal in everyone.  
Bowel inflammatory indexes 
To evaluate the bowel inflammation we performed fecal calprotectin and 
permeability test in  49/80 and 22/80 patients respectively, and we found 
that 10/49 presented a positive value of fecal calprotectin while  3/22  
showed an  altered result of permeability test. We repeated the test in 17/49 
and 9/22 and we found in 4/17 and in 1/9 pathological values respectively.  
Computerised bone mineralometry 
At the moment of the first biopsy 39/80 patients underwent a 
computerised bone mineralometry study and 3/39 presented Z-score values 
compatible with an osteoporosis, 2 of them began a GFD while another 
continued a gluten containing diet for parental decision. We repeated the 
exam in 7/39 and all were normal after 2 years of follow-up.   
Histology, immunohistochemical analysis  
All patients presented an intestinal mucosa normal from an 
architecturally point of view, 36 patients were M0 and 44 M1. 75 patients 
underwent an immunohistochemical analysis. 44/75 (58.6%) patients 
presented a value of CD3+ cells higher than cut-off and 53/75 (70.6%) an 
increased  value of γδ+ cells. Even in the lamina propria 49/75 (65.3%) 
patients presented a number of CD25+ cells higher than cut-off (Tab.2).  
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 Second biopsy  
29/67 patients that continued a gluten containing diet underwent a 
second biopsy after two years of follow-up. In 28/29 for the positivity for 
EMA and/or elevated values of anti-TG2 antibodies and only in one case 
the biopsy was performed because of invalidating abdominal pain even 
without a positive serology. 7/29 developed an intestinal atrophy receiving 
diagnosis of CD and beginning a GFD. In 22/29 the mucosa continued to be 
normal and 6/22 were M0 and 16/22 were M1 (Tab. 1). In 21/22 patients 
with persistently normal intestinal mucosa we performed an 
immunoistochemical analysis; 15/21 (71.4%) patients presented a value of 
CD3+ cells higher than cut-off not statistically different from patient with 
normal mucosa at the moment of the first biopsy; 20/21 (95.2%) presented 
an increased  value of γδ+ cells, in this case there was a difference 
statistically significant from the time of the first biopsy (Tab 2). In the 
lamina propria 11/21 (52.3%) patients presented a number of CD25+ cells 
higher than cut-off. Only one patient had already performed a third biopsy 
that was still normal.   
Deposits 
 41/80 patients were evaluated for the presence of intestinal deposition of 
IgA anti-TG2 and 27/41 (65.8%) were positive with a concordance index of 
78.0% (32/41) with the positivity of serum anti-TG2, the values of anti-TG2 
in patients without deposits were statistically lower than those of patients 
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posits for intestinal deposits (p < 0.05); in  most cases they presented a 
patchy distribution of deposits with tracts of clear positivity and tracts with 
absent signal. 29/29 patients that underwent a second biopsy were analyzed 
for intestinal deposits and we found that 21/29 (72.4%) of them were 
positive for intestinal deposits, 7/21 presented atrophic mucosa. The 
number of positive patients had no statistically significant increase . 
Searching for markers predictive of  atrophy developing 
We compared with a Pearson’s Chi-Square test different parameters to 
find markers that at the moment of the diagnosis could help us to identify 
those patients who had the risk to develop an atrophy.  The only parameter 
that  was near to significant value was the belonging  to “at risk 
group”(Tab. 3).  
 
Discussion 
The aim of our work was to evaluate the natural history of patients with 
positive serology for CD but with a normal intestinal mucosa, the so-called 
potential coeliac patients. This kind of patients is increasing, perhaps 
because of the screening of population “at risk” or because nowadays the 
attention for CD is higher than in the past. The percentage of these patients 
is now near  20% of patients with positive serology that undergo a small 
intestinal biopsy. All the patients evaluated for HLA except for one 
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presented an HLA compatible with CD so we could think that the 
probabilities that  positive serology is a laboratory mistake is very low. 
Some works in literature state that this absence of intestinal damage 
could be connected with a low amount of gluten in the diet, for example in 
first degree relatives of coeliac patients (Maki M 1992; Valletta E 2002); 
our data showed that these patients had a daily gluten intake equivalent to 
those of control patients matched for age and sex.   
These patients are often asymptomatic or with light symptoms that are 
sometimes transient and that in some cases solve even on a free diet; the 
symptomatic patients began a gluten free diet but not always there was a 
gluten-dependence of their symptoms. As concerns patients that had 
continued a gluten containing diet we found that there was no significant 
alteration of the principle nutritional parameters during the follow-up. 
At the moment of first biopsy the anti-TG2 titres was lower than that 
showed by coeliac patients with atrophy as already showed in a previous 
work (Paparo 2005), except for a few number of patients. The majority of 
them during the follow-up became negative or presented fluctuant values of 
anti-TG2 or EMA. These cases  were more frequent among those who at the 
beginning had a lower titre of anti-TG2.  
As concerns the histological and immunoistochemical parameters we 
confirmed that in the majority of patients there  are signs of cells activation 
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with increased values of CD3+ positive cells and above all gamma/delta+ 
cells higher than cut-off as already showed (Paparo et al 2005)  
The markers predictive of evolution to frank atrophy remain to be 
assessed. In particular data in literature show that intestinal deposits could 
be present at a mucosal level before the appearing of anti-TG2 in serum 
(Kaukinen K 2005).  So that their detection could be the most sensitive and 
specific test for diagnosis of CD. Our work showed  that there is a 34.1% of 
patients that are negative for intestinal deposits of IgA anti-TG2 even in 
presence of serum EMA and/or anti-TG2; in particular not always there is a 
concordance between the presence of intestinal deposits and serum anti-
TG2 titers higher than cut-off.  Anyway there was no difference in the 
positivity of intestinal deposits between those patients who developed 
atrophy and those who continued to have a normal mucosa after 2 years of 
follow-up.  
In literature there is no accordance on which is the better diagnostic and 
therapeutic protocol for patients with potential CD. There is no doubt that 
some subjects develop an intestinal atrophy but there is even a 7.4% that 
become persistently and completely negative.  
The data, obtained by this study, are very interesting, but they are not 
conclusive. A prospective and randomized study with longer follow-up is 
necessary. 
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Tab.1 Summary of patients and dietary assessment  
 
 
 
 
 
80 
Patients with Normal 
Mucosa 
16 
Gluten free diet  
64 
Gluten containing diet 
16 
Partial or complete 
response 
6 
No response   
3 
Continued a gluten free 
diet 
3 
Started a gluten free 
containing  again 
2 repeated Second biopsy
4  
the response is not 
valuable yet 
64 follow-up every 
six months 
27 repeated the 
biopsy 
20 Normal mucosa 
7 developed atrophy2 normal mucosa 
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Tab. 2  Immunohistochimical analysis in patients with normal intestinal 
architecture.  
Immunoistochemical parameters First biopsy 
 
N=75 
Second biopsy  
 
N=21 
P value 
CD3+ cells 
( > 35 mm/epithelium) 
44/75 (58.6%) 15/21 (71.4%) P =0.2 
γδ+ cells 
(> 3.2 mm/epithelium) 
53/75 (70.6%) 20/21(95.2%) P=0.019 
CD 25 + cells 
(4 cells / mm2 lamina propria) 
49/75 (65.3%) 11/21(52.3%) P=0.27 
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Tab.3 Pearson’s Chi-Square test between different parameters.  
Parameters at the time of first 
biopsy 
CD potential patients 
who developed atrophy 
N°7 
CD potential patients who 
continued to have Normal 
Mucosa N°22 
P value 
Familiarity 
 
4 (57.1%) 7  (31.8%) P =0.22  
Autoimmunity 
 
2 (28.5%) 5 (22.7%) P=0.75 
Familiarity+autoimmunity 
 
6 (85.7%) 11 (50%) P=0.09 
Marsh 1 
 
4 (57.1%) 14 (63.6%) P =0.75 
Increased value of γδ+ cells 
 
5 (71.4%) 17(77.2) P=0.75 
Serology persistently positive 
 
5 (71.4%) 14 (63.6%) P=0.70 
Presence of intestinal deposits 
 
 6 (85.7%) 15 (68.2%) P=0.36 
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3. IMMUNOLOGIC MARKERS IN POTENTIAL COELIAC 
DISEASE: CYTOKINES AND T REGULATORY CELLS 
After a study of clinical, biological and histological features of potential 
CD, the aim of my research was to characterized the immune respose in the 
intestine of patients with potential CD, in particular to clarify the early 
immunological events leading to enterophaty in the small intestine. 
 
Introduction 
Evidence suggests that coeliac disease develops gradually from small 
bowel mucosal inflammation to crypt hyperplasia and eventually to overt 
villous atrophy. The immunological mechanisms that in the potential 
coeliac mucosa are able to prevent the progression towards a complete 
mucosal damage are not yet known. Very likely, there is an interplay 
between an adaptive immunity characterised by a specific and memory T 
cell response, innate immunity involving less specific mechanisms and 
immune regulation mediated by IL-10.  
There is strong evidence that CD4+ T cell-mediated hypersensitivity 
plays a major role in tissue injury. Lamina propria CD4+ T cells are 
phenotypically activated and produce large amounts of Th1 cytokines in 
response to gluten stimulation (Nilsen EM 1998, Breese EJ 1994). IFN-γ 
seems to play a central role. IFN- γ production is massively increased in 
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untreated coeliac mucosa and in vitro its secretion can be observed in organ 
cultures from treated CD patients and in lamina propria derived T cell 
clones upon stimulation with gliadin peptides (Nilsen EM 1998, Troncone 
R 1998). Many important questions remain however regarding factors 
which induce and maintain Th1 cell polarisation in CD. Paradoxically, 
IL12, the major Th1 inducing cytokine, is undetectable in the mucosa of 
active CD (Nilsen EM 1998, Monteleone G 2001). IFNα, another cytokine 
able to promote Th1 differentiation and IFNγ production in humans, is 
expressed in the mucosa of untreated CD (Monteleone G 2001). In 
addition, it was showed the occurrence of coeliac disease in patients 
receiving IFNα therapy, suggesting a role for this cytokine in promoting 
the local immune response in CD (Monteleone G 2001). Furthermore, in 
CD but not in normal duodenal mucosa, there is production of active IL18, 
a cytokine with crucial role in maintaining Th1 response in human disease 
and experimental models (Salvati VM 2002). Finally, it has recently been 
proposed that IL15, a cytokine that is able to expand Th1 cell 
differentiation under particular conditions, may be involved in the CD 
immune response (Maiuri L 2000, Seder RA 1996). 
However, the transcriptional mechanism that underlie the distinct Th1 
type cytokine repertoire in CD remain unknow. A crucial transcription 
factor involved in the early phase of Th1 differentiation is T-bet, a novel 
member of the T-box family of transcription factors. T-bet drives chromatic 
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remodelling of the IFNγ locus. T-bet RNA transcripts and proteins are 
enhanced in biopsies from untreated CD patients (such as  in Crohn’s 
disease). The factors which induce T-bet in CD remain to be determined 
but some observations underline the relevance of the STAT-1 signalling 
pathway (Monteleone I 2004). Furthermore, STAT-1 and Interferon 
Regulatory Factor(IRF)-1, the transcription factors downstream the 
signalling pathway elicited by IFN-γ, are activated in untreated coeliac 
mucosa and can be induced in vitro in organ cultures from treated CD 
patients upon stimulation with gliadin peptides and this effect is prevented 
by a neutralizing IFNγ antibody (Salvati VM 2003). Anti sense 
oligonucelotides able to block STAT-1 signaling pathway prevent in vitro 
in organ cultures from treated CD patients IFNγ induced gene production 
of ICAM-1 and B7-1. The positive feedback regulation between 
IFNγ/STAT-1/IRF-1 is one of the most important mechanism that maintain 
autoimmunity in other Th1 mediated immune disease (Suk K 2001, 
Nakazawa T 2001). The molecular mechanism that underlies the ability of 
IRF1 to promote Th1 cell polarization is not fully understood. It is unlikely 
that IRF-1 directly affects transcription of the IFNγ gene, because no 
binding sites for IRF-1 have been reported in the promoter of the IFNγ 
gene. The more plausible explanation is that IRF-1 facilitates indirectly the 
induction of Th1 cells by positively regulating the synthesis of Th1-
inducing cytokines, such as IFNα, IL15 and IL18 (Fujita T 1989, Fantuzzi 
 80
G 2001). It would also be important to emphasize that these cytokines can, 
through the induction of IFNγ, eventually enhance transcription of IRF-1 
and generate a positive feedback loop able to maintain and expand the Th1 
response in CD. In addition, IRF-1 can contribute to amplify and maintain 
chronic inflammation by its ability to modulate several immunoregulatory 
genes, as well as to facilitate the recruitment of inflammatory cells within 
the inflamed tissue up-regulating the expression of vascular cell adhesion 
molecule-1 (Taniguchi T 2001, Kamijo R 1994, Kimura T 1996). 
Recently, several studies have suggested that immunosuppressive 
cytokines such as IL-10 and TGF-β, have an important role in maintaining 
of intestinal tolerance.  In particular, mice which are genetically deficient 
for IL-10 develop a severe form of enterocolitis, similar to human 
inflammatory bowel disease (IBD) (Kuhn R 1993), and have increased 
susceptibility to autoimmune diseases such as rheumatoid arthritis 
(Samoilova EB 1998) and experimental autoimmune encephalomyelitis 
(EAE) (Bettelli E 1998). On the other hand, colitis, which develops in 
SCID mice post transfer of CD4+CD45RBhigh T cells, can be prevented by 
IL10 (Powrie F 1994).  Generally considered as Th2 cytokine, IL-10 has a 
crucial role in the differentiation of the subset of CD4+ T regulatory cells, 
known as Tr1 cells (Roncarolo MG 2001). 
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In CD the levels of IL10 are higher in untreated CD patients if compared 
to treated CD patients and controls, but the ratio IL-10/IFNγ is significantly 
lower.   
To better understand the onset of CD we focused our interest on 
potential CD this condition represent a good in vivo model to know the 
immunological events that prevent the progression towards a complete 
mucosal damage.  
Two different approaches have been designed to achieve this aim: 
a. Analysis of cytokines and transcription factor involved in T cell 
activation (IL-2), Th1 differentiation (IFN-γ, T-bet, IRF-1) and 
immune regulation (IL10) in potential CD by real-time PCR 
b. Analysis of  T regulatory  cells  (CD4+CD25+FOXP3+, 
CD4+IL10+IL4- and CD4+ IL10+IL4+ Th2 cells) in potential CD 
by flow cytrometric. 
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A. Analysis of cytokines and transcription factor involved in T cell 
activation (IL-2), Th1 differentiation (IFN-γ, T-bet, IRF-1) and 
immune regulation (IL10) in potential CD by real-time PCR 
The first objective of this line of my research was characterized early 
immunological markers in potential CD by analysis of genes with crucial 
role in T cell activation (IL-2), Th1 differentiation (IFN-γ, T-bet, IRF-1) 
and immune regulation (IL10).  
  
Patients 
For  this aim, by real time PCR analysis we studied duodenal biopsies 
from: 16 controls (mean age: 5,3 yrs; range: 1.7-13.9) 17 untreated (mean 
age: 17.6 yrs; range: 0.75-13.3) and 15 potential coeliac patients (mean 
age: 7.2 yrs; range: 0.83-13.75).  
Control patients underwent upper gastrointestinal endoscopy because of 
the presence of gastrointestinal symptoms (abdominal pain, 
gastroesophagel reflux, emesis, failure to thrive). Duodenal mucosa was 
histologically normal in all of them. In 9/16 patients immunohistochemistry 
was performed. One patient presented an increase of intraepithelial 
lymphocytes (42 cells/100 enterocytes) and in 5 controls an increased 
expression of CD25+ lamina propria mononuclear cells was observed 
(range 4-14 cells/mm2 lp).  
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Potential coeliac patients were characterised by the presence of coeliac 
specific autoantibodies (EMA and anti TG2), the presence of HLA DQ2 
and/or DQ8, but a histologically normal mucosa (Marsh 0-1). Two patients 
were first degree relatives of coeliac patients, 9 patients were investigated 
for coeliac disease because of abdominal pain, short stature, diarrhea and 4 
patients were detected by screening. In all potential coeliac patients 
immunohistochemistry was peformed. The presence of more than 35 
intraepithelial lymphocytes was defined as Marsh 1 lesion. In 9/15 patients 
a Marsh 1 lesion was observed. In all of them signs of T cell activation 
such as an increase of CD25+ and ICAM-1 expression in the lamina 
propria and HLA DR in the crypts were also observed. Particularly, in 6 of 
these 9 patients we could observe an increase of both TCR γδ + T cells in 
the epithelium and CD25+ cells in the lamina propria.  
In 6 potential coeliac patients a Marsh 0 lesion was reported. In 3 of 
these patients signs of T cell activation were reported. Only in one patient 
we observed an increase of both epithelial TCR γδ + T cells and lamina 
propria CD25 + cells.  
Untreated coeliac disease was diagnosed in accord to ESPGHAN criteria 
(Working Group of ESPGAN 1990). 
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Results 
IL-2 RNA expression is increased in duodenal mucosa from potential 
CD patients. 
We analysed duodenal mucosa from 11 controls, 11 potential coeliac and 
12 untreated coeliac patients for IL-2 RNA expression by real-time PCR. 
We observed a significant increase for IL-2 RNA expression in potential 
coeliac mucosa if compared to control (p<0.02) and to untreated coeliac 
patients (p<0.004) (Fig. 1). We didn’t observe any difference between 
untreated coeliacs and control patients. 
  
Th1 differentiation markers are expressed in duodenal mucosa from 
potential CD patients 
We analysed expression of T-bet, IRF-1 and IFNγ in duodenal biopsies 
from 16 controls, 15 potential coeliac patients and 17 untreated coeliac 
patients.  
For T-bet RNA expression we could observe a significant increase in 
untreated coeliac mucosa if compared to control mucosa (p<0.02). In 
potential coeliac patients because of the wide confidence interval means 
were not statistically different neither compared to control patients nor to 
untreated coeliacs (Fig. 2).  
Similarly, we observed for IRF-1 RNA expression a significant increase 
in untreated coeliacs if compared to control patients (<0,003). Interestingly, 
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in potential coeliac mucosa IRF-1 RNA levels were significantly lower if 
compared to untreated CD (p<0.02) (Fig. 3). 
We found a significant increase of IFNγ RNA expression in potential CD 
if compared to control patients (p<0.0001) (Fig. 4). Interestingly, IFNγ 
expression in potential coeliac mucosa correlated significantly with 
intraepithelial lymphocyte infiltration (p<0.008, Pearson r=0.64 (Fig. 5). 
To support this observation we found that in potential CD patients with 
Marsh 1 lesion IFN-γ expression was significantly over-expressed if 
compared to potential CD patients with Marsh 0 and controls (p<0.0001). 
In Marsh 0, instead, IFN-γ levels did not differ significantly from control 
patients (p=0.178). Remarkably, even if increased in potential CD mucosa 
IFN-γ levels were still significantly down-regulated if compared to 
untreated CD (p<0.0001) (Fig. 4).   
 
IL-10/IFNγ ratio is increased in duodenal mucosa from potential Marsh 0 
CD patients 
We analysed IL-10 RNA expression in 16 controls, 15 potential CD (9 
Marsh 1 and 6 Marsh 0) and 17 untreated CD patients. 
In contrast to IFN-γ RNA expression we observed for IL-10 RNA 
expression a significant up-regulation in Marsh 0 CD patients if compared 
to Marsh 1 lesion (p<0.005) and control patients (p<0.001) (Fig. 6). The 
inverse correlation between IL-10 and IFN-γ RNA expression was even 
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more striking and became significant in untreated CD patients (Pearson r=-
0,62 <0,007). As a consequence when we analysed the ratio between IL-10 
and IFN-γ RNA levels we observed that in Marsh 0 potential CD patients 
the ratio was significantly over-expressed if compared to potential CD 
patients with Marsh 1 lesion (p<0.001), to untreated CD (p<0.0001) and 
even to control patients (p=0.053). In untreated CD patients the ratio was 
significantly down-regulated if compared to control patients (p<0.001) 
(Fig. 7). 
 
B. Analysis of  T regulatory  cells  (CD4+CD25+FOXP3+, 
CD4+IL10+IL4- and CD4+ IL10+IL4+ Th2 cells) in potential CD by 
flow cytrometric. 
On the basis of the preceding data, showed that in the early phase of the 
potential CD (Marsh 0) T cells are activated and committed to Th1 and the 
ratio between was increased significantly than Marsh 1 lesion and untreated 
CD; we suppose that regulatory mechanisms might down-regulate T cell 
mediate immune response.  
Thus, the second objective of this line of my research was to analyse in 
the different stage of coeliac enteropathy the type and percentage of 
regulatory T cell populations mainly CD4+CD25+FOXP3+ regulatory 
cells, CD4+IL10+IL4- (known as Tr1) and CD4+IL10+IL4+ Th2 cells.  
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Patients 
For Intracellular Cytokine Detection by Flow Cytometry, 18 controls 
(mean age: 10.5 yrs; range: 1.3-17.6 ) 26 untreated (mean age: 6.7  yrs; 
range: 1-17.8 ) and 27 potential coeliac patients (mean age: 10 yrs; range: 
2-17.3) were recruited.  
Control patients underwent upper gastrointestinal endoscopy because of 
the presence of  gastrointestinal symptoms (abdominal pain, 
gastroesophagel reflux, vomiting). Two patients were affected by colonic 
inflammatory bowel disease. Four patients were Helicobacter pylori 
positive. Duodenal mucosa was histologically normal in all of them. In 
3/18 patients immunohistochemistry was performed. No patient presented 
an increase of intraepithelial lymphocytes or of CD25 lamina propria 
mononuclear cells. Only in one patient an increase of density of cells 
expressing TCR γδ+ in the intraepithelial compartment (27 cells/ mm 
epithelium) was observed. 
Potential coeliac patients were defined as mentioned above. Six patients 
were first degree relatives of coeliac patients, nine asymptomatic patients 
were detected by screening (seven patients were affected by insulin 
dependent diabetes mellitus (IDDM) and two by thyroiditis), the others 
were investigated for coeliac disease because of abdominal pain, diarrhea, 
growth failure, weight loss, vomiting and anemia. In 18/27 potential CD 
patients a Marsh 1 lesion was observed. In 15 of them 
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immunohistochemistry was peformed and revealed in 13 patients the 
presence of immunological features of T cell activation such as an increase 
of CD25+ cells, TCR γδ+  intraepithelial lymphocytes, ICAM-1 expression 
in the lamina propria and HLA DR in the crypts. In 9/27 potential coeliac 
patients a Marsh 0 lesion was reported; in 4 of them we observed an 
increase of both TCR γδ+ intraepithelial lymphocytes and CD25+ cells in 
the lamina propria, while in 6 only an increase of TCR γδ+ intraepithelial 
lymphocytes and in 5 only an increase of CD25+ lamina propria 
mononuclear cells were reported.  
  
Results  
IL-10 in duodenal coeliac mucosa derives from T cells 
In accord to RNA expression we revealed by FACS analysis a significant 
increase of the percentage of IL-10 producing cells in the mucosa of 
potential coeliac patients (p<0.003) compared to control patients. We also 
observed an increased percentage of IL-10 producing cells in untreated 
coeliac patients (p<0,005).  
In order to investigate the role of IL-10 we characterised by FACS 
analysis the phenotype of IL-10 producing cells. We performed three-
colour staining with CD56, CD3 and IL-10. We analysed in the gate of IL-
10 positive cells the percentage of CD3+ CD56- (T cells), CD3- CD56+ 
(NK) and CD3+ CD56+ (NKT cells) which are the main producers of IL-
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10 in the mucosa. We could observe that in all groups of patients the mean 
percentage of IL-10 positive cells was significantly  higher in the CD3+ 
CD56-  population (Fig. 8). 
 
Increased percentage of IL10+ cells expressing CD4 surface marker in 
the duodenal mucosa from Marsh 0 potential coeliac patients 
Since different populations of T cells able to counteract Th1 immune 
response such as Tr1 cells (CD4+ IL10+ IL4-), Tregs 
(CD4+CD25+FoxP3+) and Th2 cells (CD4+IL10+IL4+) in the intestinal 
mucosa express CD4 surface antigen we analysed by double staining the 
percentage of IL10+ CD4+ cells.  
Interestingly, we observed that the percentage of CD4+ IL10+ T cells was 
significantly increased in Marsh 0 if compared to control patients (p<0,03) 
and to untreated CD patients (p<0,001) and was near to significance if 
compared to Marsh 1 lesion (p=0,07) (Fig. 9) suggesting the presence of 
immunoregulatory mechanisms in Marsh 0 potential CD which is also 
supported by the high IL-10/IFN-γ RNA ratio mentioned above.   
In untreated CD the percentage of CD4+IL10+ cells was significantly 
down-regulated if compared to control (p<0,004), Marsh 1 (p<0,04) and 
Marsh 0 patients (p<0,001).  
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Increased percentage of CD4+CD25+FoxP3+ cells in duodenal mucosa 
from coeliac patients 
To characterise the  phenotype of CD4+ cells we performed three-colour 
staining for IL10/CD4/IL4 and CD4/CD25/FoxP3. 
The percentage of IL-10 positive cells that express CD4 and IL4 (Th2) 
was at a first glance not significantly different in all groups analysed. 
However, when we splitted the control group in normal controls and 
Helicobacter pylori positive controls we could observe a significant 
increase of the percentage of Th2 cells in Marsh 0 and untreated CD 
patients  if compared to control patients (p<0,03 and p<0,05 respectively) 
(Fig. 10). 
We couldn’t observe any difference in the percentage of IL-10 positive 
cells that express CD4 but not IL4 (Tr1) (Fig. 11). 
Interestingly, a significant increase was observed in untreated CD, Marsh 
0 and Marsh 1 potential CD mucosa for CD4+ cells that expressed CD25 
and FoxP3 if compared to control mucosa (p<0,0001, p<0,0028 and 
p<0,0008 respectively) (Fig. 12).  
 
Discussion  
In this line of my research, for the first time, we focused our interest on 
potential CD and, in particular, on their intestinal immune response, 
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representing this condition a good in vivo model to know the early  
immunological events implicated in the onset of coeliac disease.  
The first object of this study was to analyse the state of activation of 
mucosa T cell in potential CD. At this aim, we studied the RNA expression 
for IL-2 by quantitative RT-PCR. IL2 is an important growth factor for T 
lymphocytes and is involved in T cell activation and differentiation (Jain J 
1995). We observed a increase of IL-2 RNA expression in potential CD 
patients if compared to controls and untreated coeliacs, while there were not 
any difference between untreated CD and control patients, in accord to our 
previous data obtained (Salvati MV 1999). Similar to our findings, 
Westerholm-Ormio M et al showed by in situ hybridation the higher density 
of IL-2 in lamina propria of family members of patients with CD and 
dermatitis herpetiformis (Westerholm-Ormio M 2002).  
Then, we studied transcription factors involved in Th1 differentiation, 
such as T-bet. It is a crucial transcription factor involved in the early phase 
of Th1 differentiation. T-bet is able to control induction of IFNγ and 
repression of IL-4 and IL-5. Thus, T-bet initiates Th1 lineage development 
from naive Th cells both by activating Th1 genetic programs and by 
repressing the opposing Th2 programs (Szabo SJ 2000). For T-bet RNA 
expression we found a significant increase in untreated coeliac mucosa if 
compared to control mucosa, similar results we showed for IRF-1, 
confirming our previous data (Monteleone I 2004). In potential CD, the 
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levels of T-bet were higher than controls but not statistically significant. 
Likely, the differentiation in Th1 starts in a early phase of disease, as 
showed in a model of uveitis in rat, in which T-bet were observed at 8 h, 
significantly increased 24 h, and decreased 48 h after lipopolysaccharide 
(LPS) injection (Li B 2006).  
Moreover, we showed in potential CD mucosa a significant increase of 
IFNγ RNA expression. In particular, IFNγ levels correlated with 
intraepithelial lymphocyte infiltration, it agrees with previous data that 
showed higher density of IFNγ positive cells in potential CD patients with 
high γδ TCR+ intraepithelial lymphocytes (IELs) (Westerholm-Ormio M 
2002). 
Our data suggest that in potential CD despite the absence of mucosal 
damage T cells seem to be activated and differentiating towards a Th1 
pattern, as supported by a significant increase of IL2, T-bet and IFNγ. We 
hyphotesize that regulatory mechanisms might contribute to prevent the 
progression towards a complete mucosal damage.  
Therefore, we investigated the presence of immunoregulatory cytokines 
able to contrast the ongoing Th1 response in potential CD. We analysed to 
this purpose IL-10 expression, a key cytokine involved in immune 
regulation.  The levels of IL-10 were significantly increased in T0 Marsh 
group of patients than controls, while in T1 Marsh group they were 
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reduced. In particular the ratio between IL 10 and IFN-γ  was increased in 
group T0 if compared to active coeliac patients and group T1.  
Further, we hypothesized that a crucial role in the maintainment of 
mucosal inflammation in untreated coeliac disease is determined 
synergistically by two immunological mechanisms: first, an excessive IFNγ 
production due to IRF-1/STAT-1 positive feed-back regulation and second, 
an inefficient immune suppression as evidenced by a low ratio IL-10/IFNγ. 
 Interestingly, in potential coeliac mucosa IRF-1 was significantly lower 
if compare to untreated CD. IRF-1 can have a protective role in intestinal 
inflammation, with a possible anti-inflammatory and/or restorative role. In 
fact a recent study shows that the administration of dextran sulphate 
sodium or trinitrobenzene sulfonic acid leads to a dramatic increase in 
lethality and colitis severity in IRF-1 knockout mice (Siegmund B 2004).  
In conclusion in potential CD mucosa, T cells are committed and 
activated in the early phase of the disease (T0 Marsh). In this stage the 
presence of IL 10 producing lymphocytes down regulates IFNγ production. 
Subsequently, during the infiltrative phase (T1 Marsh), the down regulation 
of IL10 favours the up regulation of IFNγ production and thus might drive 
the mucosal damage.    
A further data that support the hypothesis that the regulatory 
mechanisms might downregulate T cell mediate immuno-response in the 
early phase of CD enterophaty is the increased number of CD4+IL10+ cells 
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in mucosa of potential CD with T0 Marsh lesion. But in untreated CD the 
percentage of CD4+IL10+ cells was significantly down-regulated if 
compared to control, Marsh 1 and Marsh 0 patients. Very likely, IL-10 
producing cells in untreated CD express CD8+ as suggested by 
Hammarstrom ML and colleagues (Forsberg G 2007).  
Interestingly, a significant increase was observed in untreated CD and 
potential CD for CD4+CD25+FOXP3+ cells. Since the percentage of 
double positive CD4+IL10+ cells is significantly higher in Marsh 0 
potential CD if compared to control and untreated CD patients, very likely, 
the CD4+CD25+FoxP3+ population in potential CD is able to produce IL-
10 and regulate  Th1 immune response. 
Our data suggest that regulatory mechanisms play a crucial role to 
downregulate the inflammation in early phase of CD, the subsequent events 
leading  to failure of these regulatory mechanisms remain  to know.  
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   IL2 RNA expression in duodenal mucosa 
Fig. 1  IL2 RNA expression is significantly increased in duodenal 
mucosa from potential CD patients if compared to control (p<0.02) 
and to untreated CD patients (p<0.004). There are not differences 
between untreated CD and controls. Each point represents the value 
(relative IL2/L32 RNA expression) of IL2 taken from a single 
subject. Horizontal bars indicate median values. 
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     T-bet RNA expression in duodenal mucosa 
Fig. 2 T-bet RNA expression is significantly increased in duodenal 
mucosa from untreated CD patients if compared to controls 
(p<0.02). In potential CD patients there is a wide confidence 
interval, for this reason  means are not different neither compared 
to controls nor to untreated CD patients. Each point represents the 
value (relative T-bet/L32 RNA expression) of T-bet taken from a 
single subject. Horizontal bars indicate median values. 
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IRF-1 RNA expression in duodenal mucosa 
Fig. 3 IRF-1 RNA expression is significantly  increased in 
duodenal mucosa from untreated CD patients if compared to 
controls (p<0.003) and to potential CD patients (P<0.02). Each 
point represents the value (relative IRF-1/L32 RNA expression) 
of IRF-1 taken from a single subject. Horizontal bars indicate 
median values. 
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Potential CD 
N=15 
Untreated CD 
N=17 
Marsh 1 
N=9 
Marsh 0 
N=6 
Controls 
N=16 
   IFNγ RNA expression in duodenal mucosa 
Fig. 4 IFNγ RNA expression is increased in duodenal mucosa 
from untreated CD patients if compared to controls and potential 
CD (0.00001 and 0.0001 respectively).  
In potential CD patients with Marsh 1 intestinal lesion (Marsh 1) 
there is a significant increase of IFNγ RNA expression if 
compared to controls and potential CD with Marsh 0 (Marsh 0)   
(p<0.0001). Each point represents the value (relative IFNγ/L32 
RNA expression) of IFNγ taken from a single subject. Horizontal 
bars indicate median values. 
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Correlation between IFNγ expression and intraepithelial 
lymphocyte infiltration in duodenal mucosa of potential CD 
patients  
Fig. 5 IFNγ expression in potential CD mucosa correlates with 
intraepithelial lymphocyte infiltration (p<0.008, Pearson r=0.64) 
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Fig. 6  IL10 RNA expression is increased in duodenal mucosa 
from potential CD patients with Marsh 0 lesion if compared to 
Marsh 1 lesion and controls (0.005 and 0.001 respectively).  
 
            IL-10 RNA expression in duodenal mucosa 
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       IL-10 / IFN-γ Ratio in duodenal mucosa  
Fig. 7 IL-10 / IFN-γ ratio is higher in Marsh 0 potential CD than 
Marsh 1 potential CD,  untreated CD and  controls (p<0.001, 
p<0.0001 and p=0.053 respectively). 
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               Phenotype of IL 10 producing cells in duodenal mucosa  
Fig. 8 We analysed in the gate of IL10+ cells the percentage of 
CD3+CD56- (T cells), CD3-CD56+ (NK) and CD3+CD56+ (NKT 
cells). The mean percentage of IL10 positive cells is significantly higher 
in the CD3+ CD56- population.  
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      CD4+IL10+ T cells in duodenal mucosa 
Fig. 9 Increased percentage of CD4+IL10+ T cells in duodenal 
mucosa from potential CD patients with Marsh 0 lesion 
compared to controls, untreated CD and Marsh 1 patients 
(p<0.03, p<0.001, p=0.07 respectively). 
In untreated CD patients CD4+IL10+ cells are down-regulated 
than controls, Marsh 1 and Marsh 0 patients (p<0.004, p<0.04, 
p<0.001 respectivaly). 
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                  CD4+IL10+IL4+ (Th2) cells in duodenal mucosa 
Fig. 10 The percentage of CD4+IL10+IL4+ cells is not 
significantly different in all groups analysed. 
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                  CD4+IL10+IL4- (Tr1) cells in duodenal mucosa 
Fig. 11 The percentage of CD4+IL10+IL4- (Tr1) cells is not 
significantly different in all groups analysed. 
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                  CD4+CD25+Foxp3+ cells in duodenal mucosa 
Fig. 12 Increased percentage of CD4+CD25+Foxp3+ cells in 
duodenal mucosa of untreated CD, Marsh 0 and Marsh 1 potential 
CD compared to controls (p<0.0001, p<0.005 and p<0.001 
respectively).  
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4. IMMUNOLOGIC MARKERS IN COELIAC PATIENTS WITH 
SELECTIVE IGA DEFICIENCY. 
Finally, we focused our interest on a particular condition, the CD in 
patients with selective IgA deficient (IgAD). Screening for CD is a special 
challenge in IgAD since the IgA class CD associated autoantibodies are not 
produced. In addition, enhanced T cell activation is present in the intestine 
of IgAD making difficult the differential diagnosis with potential CD. This  
study had the aim to find immunological markers that could improve the 
diagnostic accuracy of CD in  IgAD subjects.  
 
Introduction 
Selective IgA deficiency (IgAD) is the most common primary 
immunodeficiency, characterized by total IgA serum level below 0.05 g/L 
with IgM and IgG serum remaining within normal ranges and absence of 
IgA in the secretions of the patients (Klemola T 1987). It is a heritable 
condition associated with the ancestral haplotype HLA-A1, Cw7, B8, DR3, 
DQ2, occurring with a prevalence of 1:300-1:800 in the European normal 
population (Koistinen J 1975, Vorechovsky V 2000). This condition may 
predispose to recurring respiratory, urinary, or gastrointestinal tract 
infections, as well as allergy and autoimmune disorders, although 
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frequently subjects with IgAD are asymptomatic (Cunningham-Rundles C 
2001).  
Secretion of IgA is the most important defence mechanism of the 
mucosal surfaces against microbial infections and penetration of foreign 
proteins. However, in IgAD the lack of IgA containing cells is compensated 
by an excess of cells containing IgM in the small intestinal and rectal 
mucosa (Savilahti E 1973). The efficacy of IgM on mucosal surfaces is not 
well established. IgA deficient individuals often have high levels of 
antibodies to cow’s milk proteins and to other food proteins and increased 
levels of immunocomplexes containing milk proteins in their sera 
(Cunningham-Rundles C 1981). After oral poliovirus vaccination the 
patients with IgAD have an impaired capacity to eliminate poliovirus 
(Savilahti E 1988). In addition, enhanced T cell activation is present in the 
intestine of these subjects; in fact, they have a significant increase of 
CD25+ cells and high density of intraepithelial lymphocytes (IELs) in the 
jejunal mucosa (Klemola T 1988, Klemola T 1995). Finally, some of them 
have minimal morphological changes in the duodenal mucosa, which are 
recognizable only at the ultrastructural level (Giorgi PL 1986).  
IgAD is frequently associated with coeliac disease (CD) and a 10- to 20-
fold increased risk for CD may be observed in subjects affected by IgAD. 
Moreover, patients with IgAD have a higher incidence of silent forms of 
CD (Cataldo F 1998). For this reason, screening for CD is mandatory in 
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patients with IgAD, but it represents a special challenge since the specific 
IgA-class autoantibodies against gliadin (AGA), endomysium (EMA), and 
tissue transglutaminase (TG2) are not detectable. Determination of the IgG 
class of CD associated antibodies has been suggested as an alternative for 
identification of IgA deficient patients with CD, but the accuracies of these 
assays vary. IgG-TG2 measurement by enzyme-linked immunoassorbent 
assay using recombinant human (rh)-TG2 as antigen have proved to be 
highly reliable serological tests for the diagnosis of CD in patients with 
IgAD (Korponay-Szabo IR 2003), despite the diverse commercial methods 
present significant differences in terms of sensitivity and specificy (Villalta 
2007).  
More recent observations that histology has lost specificity for the diagnosis 
of CD have further increased the diagnostic difficulties; from a histological 
point of view, in fact, it is now clear that the development of the CD 
mucosal lesion is a dynamic process that may present in various stages or 
types of lesions (Marsh MN 1992). Thus, a minor abnormalities of jejunal 
mucosa, that frequently are presented in subjects with IgAD could reflect 
early and incomplete manifestations of coeliac disease. Several markers of 
gluten sensitivity have been proposed, such as the increased densities of 
IEL γδ+ or the count of IEL at the villous tip, but so far no single marker is 
considered a reliable indicator of this condition (Maki M 1991, Jarvinen TT 
2004). More recently it has been shown that intestinal deposits of anti-TG2 
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would have the best sensitivity and specificity to predict the evolution to 
over CD (Salmi TT 2006).  
In this study we investigated immunohistochemically jejunal biopsy 
specimens from patients with IgAD with or without associated CD with the 
aim to find markers that could improve the diagnostic accuracy of CD in  
IgAD subjects. In particular the density of intraepithelial γδ T cells and the 
deposition of anti TG2 IgM antibodies in duodenal mucosa were studied. 
 
Patients  
In this study jejunal biopsy specimens from 23 patients with IgAD (11 boys 
and 12 girls, mean age 7.2 years; range: 1.2 – 23.3 years) were investigated. 
Immunoglobulins were measured in serum of all patients, and in those with 
serum IgA concentration below 0.05 g/l in the presence of normal levels of 
serum IgG and IgM (>7 g/l and > 0.5 g/L, respectively) the diagnosis of  
IgAD was confirmed. None of the patients received drugs like phenytoin, 
penicillamine or captopril that might have affected the immunoglobulin 
levels. All subjects gave informed consent to the proposed study. Biopsy 
specimens from duodenum were obtained by upper gastrointestinal 
endoscopies or by Watson biopsy device. Seven of these patients (mean 
age: 7.6 years; range: 1.2 – 16 years) showed normal villous architecture in 
small intestinal mucosa (Marsh 0-1) (Oberhuber G 1999) and none of these 
had increased serum anti TG2 IgG antibodies on gluten containing diet. All 
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patients had clinical features suggestive of CD, such as recurrent non-
specific diarrhoea (n=3), abdominal pain (n=2), iron-deficiency anemia 
(n=2), weight loss (n=1), anorexia (n=1). Seven patients (mean age: 6.8 
years; range: 1.5 – 16.4 years) with IgAD were characterised by the 
presence of anti TG2 IgG antibodies in the serum and a normal architecture 
of the small intestinal mucosa (Marsh 0-1) on gluten containing diet. HLA 
class DRB1 and DQB1 molecules were determined  in 5  patients  and 5/5 
carried the CD-associated haplotypes (DQ2). They were considered 
compatible with diagnosis of potential CD. Four of these patients were first-
degree relatives of coeliac disease. In five patients there were clinical 
features suggestive of CD: two patients presented intermittent diarrhoea, 
two iron-deficiency anemia and two elevation of serum aminotransferases 
and one failure to thrive. Nine IgA deficient patients (mean age: 7 years; 
range: 1.2 – 23.3 years) with subtotal or severe partial atrophy of duodenal 
mucosa and increased serum anti TG2 IgG antibodies were considered 
compatible with diagnosis of untreated CD. 3/3 were positive for HLA 
DQ2.    
The study control group included immunologically intact patients with 
normal serum levels of immunoglobulins. From sixteen control patients (5 
girls and 11 boys; mean age: 5.1 years; range: 1 – 11.2 years) with normal 
intestine and absence of serum IgA EMA and/or anti-TG2 autoantibodies 
jejunal biopsy specimens were studied by immunohistochemical analysis 
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for the density of CD25+ cells in the lamina propria,  CD3 + and γδ+  
intraepithelial lymphocytes in the epithelium and the expression of ICAM-1 
and crypt HLA-DR. Control patients underwent 
esofagogastroduodenoscopy because of the presence of upper 
gastrointestinal symptoms (general diagnosis were: gastroesophagel reflux,  
chronic gastritis and gastric polyposis). 
Anti-TG2 IgM intestinal deposits were investigated in jejunal mucosa of 
a subgroup of eight subjects of controls described above, twelve subjects (7 
girls and 5 boys; mean age: 6.11 years; range: 2 – 12 years) with CD in 
accord to ESPGHAN criteria (Working Group of ESPGAN. 1990) and of 
nine potential CD (4 girls and 5 boys; mean age: 8.8 years; range: 3 – 16 
years), characterised by the presence of coeliac specific autoantibodies 
(EMA and/or anti TG2) of IgA class, the presence of HLA DQ2 and/or 
DQ8, but a histologically normal mucosa.  
 
 
Results 
The densities of CD25+ cells in the lamina propria and the expression of 
ICAM-1 and crypt HLA-DR of jejunal specimens   
The density of lamina propria CD 25+ cells were determined in 21 
patients with IgAD: 8 subjects with absence of anti TG2 IgG antibodies and 
a histologically normal jejunal mucosa (IgAD), 7 potential CD with 
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presence of serum TG2 IgG and a histologically normal jejunal mucosa 
(Pot.CD-IgAD), 6 CD subjects with subtotal or severe partial atrophy of 
duodenal mucosa and increased serum anti TG2 IgG antibodies (CD-IgAD).  
In 17 out of 21 (83%) specimens from IgAD patients (7/8 IgAD, 4/7  
Pot.CD-IgAD and 6/6 CD-IgAD) the number of lamina propria CD25+ 
cells was increased if compared to normal values (< 4 cells / mm2 lamina 
propria).   
In IgAD without associated CD the density of lamina propria CD25+ 
cells (mean 15.15, median 11) was significantly higher (p < 0.05) than 
control patients (mean 6, median 4.5), but significantly lower than IgAD 
patients with CD (mean 111, median 110; p< 0.005). On the contrary,  
similar densities of CD25+ cells were present in the lamina propria of 
jejunal biopsy specimens from IgAD without associated CD and IgAD 
patients with potential CD  (mean 16, median 6; p=0.5).  Also CD IgAD 
patients has more CD25+ cells in the lamina propria compared to controls 
(p<0.01), while there were not differences significantly between potential 
CD IgAD patients and controls (p=0.4). (Fig.1) 
The expression of lamina propria ICAM-1 was enhanced  in 5 of 6 
(83%) of IgAD patients without associated CD, in 4 of 4 (100%) of  IgAD 
patients with CD, and in 2 of 6 of IgAD patients with potential CD (33%). 
The difference of expression was statistically significant between samples 
from IgAD without associated CD patients and controls (p < 0.05). Instead, 
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the expression did not differ significantly between IgAD patients without 
CD and IgAD patients with potential CD and CD. 
Positive staining of crypt epithelial cells with anti-HLA DR was similar 
in IgAD patients without CD (6/6), potential CD (4/5) and CD subjects with 
IgAD (4/4).  The expression of HLA-DR positive cells did not differ in 
these three groups and controls. 
 
Infiltration of lymphocytes in the epithelial compartment of jejunal 
specimens  
CD3 + intraepithelial lymphocytes (IELs) 
The number of CD3+ lymphocytes was determined in 19 patients with 
IgAD: 8 IgAD without CD, 7 potential CD, 4 CD subjects. The density of 
CD3+ cells in the epithelial compartment was higher than cutoff (> 34 cells/ 
mm epithelium) in all IgAD CD (4/4), but only in 2/7 (28%) potential  CD 
and in 5/8 (62%) IgAD patients without CD.  
The IgA deficient patients without CD had more CD3+ cells in the 
epithelium (mean 36.7, median 40.15) compared to control patients (mean 
22.31, median 21.15; p< 0.05), but significantly the density was lower than 
IgAD patients with CD (mean 82.12, median 86.5; p< 0.01). Interestingly, 
the density of CD3+ intraepithelial lymphocytes did not present difference 
statistically significant between IgAD without CD and potential CD 
subjects (mean 32, median 29; p= 0.7). CD IgAD patients has more CD3+ 
 115
cells in the epithelium compared to controls (p<0.005), while in potential 
CD IgAD also if the number of CD3+ cells tended to be higher, there were 
not differences significantly compared to controls (p=0.07). (Fig. 2).  
T cell receptor (TCR) γδ intraepithelial lymphocytes  
The number  of TCR γδ IELs was detected in jejunal specimens of 20 
patients with IgAD: 8 without associated CD, 7 potential CD, 5 CD 
subjects. All IgAD CD patients had an increase of TCR γδ IELs in the 
jejunal epithelium (5/5), but only 3/7 (42%) potential CD and 4/8 (50%) 
patients without CD if compared to normal values (>  3.6 cells / mm 
epithelium).  
In IgAD without associated CD (mean 6.37, median 4) the number of 
TCR γδ IELs was significantly raised compared with control patients (mean 
1.6, median 1.25; p< 0.05),  but significantly lower than CD IgAD patients 
(mean 24.74, median 24.8; p< 0.005). The density of TCR γδ IELs was 
similar in IgAD and potential CD IgAD (mean 4.38, median 2.7; p=0.5). In 
CD IgAD patients the density of γδ IELs was higher than to controls 
(p<0.005), while there were not differences significantly between potential 
CD IgAD patients and controls (p=0.05), also if in the potential CD IgAD 
patients the number tended to be increased.  
Finally, in IgAD without CD (mean 16.7, median 17.1) the γδ+/CD3+ 
ratio was significantly higher (p<0.05) than in controls (mean 8.9, median 
8.4), while it was not different between these patients and subjiects with 
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potential CD and CD (mean 14.7, 27.7; median 9.2, 29.7;  p=0.7, p=0.1 
respectively). In the CD patients the γδ+/CD3 ratio was significantly 
increased (p<0.05) than in controls, but there were not differences 
significantly in the potential CD compared to controls (p=0.2) (Fig.4).  
Anti TG2 IgM intestinal deposits in patients with IgAD 
In 19 patients with IgAD anti TG2 IgM deposits were investigated. 
Jejunal mucosa from non coeliac subjects (5/5) showed IgM only inside 
plasma cells and epithelial cells. On the contrary, 6/7 untreated coeliac 
patients showed IgM deposits below the villous and crypt basement 
membranes, corresponding to the intestinal localization of TG2, apart from 
IgM inside plasma cells. In these specimens we observed a patchy 
distribution and less thick bands along the surface and crypt basement 
membranes and around mucosal vessels of the deposits. Only one patient 
presented increased density of these bands. Among the group of potential 
coeliac patients, anti-TG2 IgM deposits were noted only in one of 7 
patients. In this patient the pattern was similar to that described for patients 
with IgAD and CD. In CD patients the prevalence of intestinal anti-TG2 
deposits was significally higher than potential CD and patients without CD 
(p< 0.01, p< 0.005 respectively) (Tab. 1).   
All positive samples showed a patchy IgM deposits pattern, were 
analysed by confocal microscope to further asses the colocalization of IgM 
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deposits with TG2. Confocal analysis confirmed in all cases the 
observations previously described.  
In the control group of immnologically intact patients, coeliac subjects 
on gluten-containing diet showed elevated levels of IgM containing cells in 
the jejunal mucosa but anti TG2 IgM intestinal deposits were seen only in 
6/12 and in 1/9 potential CD patients. In all these positive specimens for 
intestinal deposition of antiTG2 IgM we observed a patchy distribution and 
less thick subephielial bands  None of controls (8/8) presented deposits.  
 
Discussion 
Findings of enhanced T cell activation are present in the intestine of 
IgAD patients. These subjects often shows pathological changes in the 
small intestinal mucosa, some of which are recognizable only at the 
ultrastructural level (Giorgi PL 1986). In addition, the density of 
intraepithelial lymphocytes and of activated CD25+ cells in both the lamina 
propria and in the surface epithelium are increased in the jejunal mucosa of 
patients with IgAD (Klemola T 1988, Klemola T 1995). Our results 
confirmed these previous data; in fact, we found an increase of the number 
of lamina propria CD25+ cells and the expression of ICAM-1 and crypt 
HLA-DR in IgAD independently from the diagnosis. In particular, IgAD 
patients without associated CD showed a density of lamina propria CD25+ 
cells higher than immunologically intact controls. The pathogenesis of these 
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mucosal lesions is not well understood. In IgAD the secretory IgA is 
severely diminished or lacking in their external secretions. Secretion of IgA 
is the most important defence mechanism of the mucosal surface against 
virus, bacteria and toxins. IgA also can complex with antigens that have 
penetrated the lamina propria and transport them across epithelial cells to 
facilitate antigen exclusion (Cunningham-Rundles C 2001). This lack of 
secretory IgAD is replaced by a compensatory increase in secretory IgM 
(Natvig IB 1997). Although secretory IgM has been shown to be 
functionally active, it is not clear that it confers the same mucosal 
protection as secretory IgA. IgA deficient blood donors harbour poliovirus 
in their intestine longer after oral vaccination, while they reached the same 
serum antibody levels than normal subjects, confirming the hypothesis it is 
due to an inefficiency of local mucosal immunoglobulins and not due to an 
inadequate serologic response (Savhilati E 1988). Over 60% of patients 
with IgAD have precipitating antibodies to bovine milk proteins and 
circulating immune complex, in which milk proteins are important antigenic 
elements, probably owing to increased penetration of food proteins through 
the intestine (Cunnigham-rundles C). It is demonstrated an abnormal 
intestinal permeability in these subjects (Pignata C 1990). Finally, IgA in 
the serum does not fix complement by classical pathway, although it can do 
so as a aggregate by the alternative pathway, it has been suggested that IgA 
acts as a “silent housekeeper”, in which foreign antigen are bound by IgA 
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into complexes and removed by the phagocytic system, but with little or no 
resultant inflammation (Jacob CM 2008). On the contrary, IgG antibodies 
are able efficiently to eliminate antigen by promoting phagocytosis, but 
they may maintain inflammatory and tissue-damaging processes by 
complement activation. IgA patients with a history of frequent respiratory 
tact infections respond to an oral cholera vaccination with significantly 
higher intestinal cholera toxin-specific IgG and IgM antibody responses 
than healthy IgAD individuals and controls (Friman V 1994). In conclusion, 
damage to the small intestinal mucosa in patients with IgAD could derive 
from abnormal microbiological or immunological processes.    
Interestingly, we found increased number of intraepithelial lymphocytes, 
in particular of CD3+ and γδ+  cells in the epithelial compartment of IgA 
deficient patients without associated CD, but the density was lower than 
IgAD patients with CD, while it did not present difference statistically 
significant compared to potential CD IgA deficient subjects.  In addition, 
our IgAD patients without CD showed a higher γδ+/CD3+ ratio than 
controls, while this ratio was similar to subjects with potential CD and CD. 
These data do not agree with results of previous studies; in these all IgAD 
patients with normal jejunum had a density of CD3+ and γδ+ cells similar 
to immunologically normal controls, only IgAD patients with a low 
frequency of infections showed an increase of  γδ+ IELs, suggesting a 
compensatory mechanism of surface protection (Nilssen DE 1993). Instead, 
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Klemola T et al (Klemola T 1995) found an increased number of γδ+ 
lymphocytes only in the jejunum of patients with IgAD and CD during 
gluten free diet when their jejunal morphology was normal. All our IgA 
deficient patients with absence of  serum IgG associated-CD antibodies and 
normal mucosa architecture at the intestinal biopsy examination had clinical 
features suggestive of CD, such as recurrent non-specific diarrhoea, 
abdominal pain, iron-deficiency anemia, weight loss, anorexia. Thus they 
could have an early CD. 
It is earlier observed that an increased density of γδ+ IELs (Iltanen S 
1999) or the count of IELs at the villous tip in the jejunal epithelium (Salmi 
TT 2006, Jarvinen TT 2004) predicts the forthcoming coeliac disease in 
autoantibody positive patients with a normal villous structure. In particular 
Paparo et al (Am J Gastroenterol 2005) suggested that a high γδ+/CD3+ 
ratio of intraepithelial lymphocytes would be a marker of genetic gluten 
intolerance. However a high count of γδ IELs is not specific for CD and 
also if the ratio γδ+/CD3+ indeed differentiates early developing CD from 
non-coeliac controls, there was a considerable overlapping between the 
groups (Spencer J 1991, Kaukinen K 2006).  
Certainly, the detection of intestinal deposits of IgA antibodies against 
TG2 strengthens the probability of CD in borderline cases where the 
histology is difficult to interpret (Salmi TT 2006). It is well know that anti-
TG2 IgA autoantibodies are produced in the intestinal mucosa (Marzari 
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2001) and they can deposit on extracellular TG2 in the small-bowel mucosa 
even when not measurable in serum (Picarelli A 1996). In the case of IgA 
deficiency, IgA deposits were missing (Korponay-Szabo IR 2003). IgAD is 
characterized by an excess of cells containing IgM in the small intestinal 
(Savilahti E 1973). Thus, we investigated the IgM antibodies against TG2 
deposits in the small intestinal mucosa of patients with IgAD to find the 
best specific disease markers able to distinguish CD patients among IgAD 
subjects. We found that 86% (6/7) of CD IgAD patients presented  specific 
intestinal deposits of IgM anti-TG2 antibodies, confirming previous data. In 
contrast with they, where the deposits were thick, with a clear localization 
below the basement membrane, along the villous and the crypt and around 
mucosal vessels in all patients with untreated CD (Korponay-Szabo IR 
2004, Tosco A 2008), in our CD IgAD patients the positivity of intestinal 
IgM anti TG2 antibodies deposits was less clear, with tracts with evident 
deposits and tracts in which these deposits were absent. In the group of 
IgAD patients with potential CD only one subjects of seven showed these 
deposits with similar of distribution described for patients with IgAD and 
CD. This prevalence is not agreed with recent data in which 85% of patients 
with potential CD turn out to be positive for intestinal deposition of anti-
TG2 IgA (Tosco A 2008). Also in our control group included patients with 
normal serum levels of immunoglobulins the data were in contrast with 
previous results. These differences of prevalence and distribution could 
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reside in a lower titer of IgM anti-TG2 antibodies and/or in a lower affinity 
of these antibodies for the intestinal transglutaminase.   
Moreover, identification of gluten-sensitive individuals in the groups of 
patients with IgAD is necessary, because it cannot be ruled out that these 
individuals, if gluten sensitive, are at risk for secondary complications of 
untreated coeliac disease such as osteopenia and lymphoreticular 
malignancy. New methods are needed to make the diagnostic procedure 
easier. 
 123
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CTR n=17 IgADp n=8 CDIgADp n=6 PotIgADp n=7
0
25
50
75
100
125
150
175
200
225
250
p< 0.05
p< 0.005
p< 0.01
C
el
ls
/m
m
2
la
m
in
a 
pr
op
ri
a
     The density of CD25+ cells in the lamina propria of duodenal 
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Fig. 1 Increased density of  lamina propria  CD25+ cells  in IgAD 
without CD (IgADp) and in IgAD patients with CD (CDIgADp) if 
compared to controls (p<0.05 and p<0.01 respectively). 
IgADp present lower density of  lamina propria CD 25+ cells than 
CDIgAp (p< 0.005), but similar to potential CD (PotIgADp) (p=0.5). 
Each point represents the density (Cells/mm2 lamina propria) of 
CD25+ cells taken from a single subject. Horizontal bars indicate 
mean values. 
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Fig. 2 Increased number CD3+ cells in the epithelium of IgAD 
without CD (IgADp) and IgAD patients with CD (CDIgADp) if 
compared to controls (p<0.05 and p<0.005 respectively). 
IgADp present lower number of CD 3+ intraepithelial lymphocytes 
than CDIgAp (p< 0.01), but similar to potential CD (PotIgADp) 
(p=0.7). Each point represents the number (Cells/mm ephitelium) of 
CD3+ cells taken from a single subject. Horizontal bars indicate 
mean values. 
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The number of T cell receptor (TCR) γδ intraepithelial 
lymphocytes (IELs) in the epithelium of duodenal mucosa  
Fig. 3 Increased number γδ IELs in the epithelium of duodenal 
mucosa of IgAD without CD (IgADp) and IgAD patients with CD 
(CDIgADp) if compared to controls (p<0.05 and p<0.005 
respectively). 
IgADp present lower number of γδ IELs than CDIgAp (p< 0.005), 
but similar to potential CD (PotIgADp) (p=0.05). Each point 
represents the number (Cells/mm ephitelium) of γδ+ cells taken from 
a single subject. Horizontal bars indicate mean values. 
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Fig. 4 In IgAD without CD the γδ+/CD3+ ratio was higher than 
in controls (p<0.05), while it was not different between these 
patients and subjiects with potential CD and CD (p=0.7 and 
p=0.1 respectively). In the CD patients the γδ+/CD3 ratio was 
significantly increased (p<0.05) than in controls.  
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Patients  Prevalence 
positivity 
% Positivity 
IgAD without CD 
(IgADp) 
0/5 0% 
IgAD with serum TG2 and 
normal mucosa 
(potential CD) 
1/7 14% 
IgAD with CD * 6/7 86% 
 
Tab. 1 Anti-TG2 IgG jejunal deposits in subjects with selective IgA 
deficiency  
 
* P < 0.005 vs  IgADp and   
  p < 0.01 vs potential CD  
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METHODS  
 
EMA AND ANTI-TG2 ANTIBODIES  
Serum IgA and IgG (for patients with IgAD) EMA were detected by 
indirect immunofluorescence on 7-µm thick frozen sections of human 
umbilical cord. Sera were tested, diluted 1:5 and 1:50, and incubated for 30 
min at room temperature. Serum was removed by washing with PBS 
solution, and the sections were exposed for 30 min to FITC-labeled rabbit 
anti-human IgA or IgG1 (1:80 and 1:100 respectively). Samples were 
considered positive if a thin fluorescent network appeared around the 
smooth muscle fibres. Positive results were quantified further by titration. 
Serum levels of IgA and IgG (for patients with IgAD) were determined 
by ELISA with a kit based on human recombinant antigen (Eu-tTg IgA and 
IgG; Eurospital, Trieste, Italy). Samples were diluited 1:26 before use and 
left to react in the wells for 60 min. Nonspecific antibodies were removed 
by washing. Horse radish peroxidase-labeled goat anti-human IgA or IgG 
were added to the wells and left to bind to the human antibodies; the excess 
conjugate was washed aways and a chromogenic substrate was added. After 
incubation for 20 min, we measured the optical density (450 nm) with a 
SpectraCount apparatus (Packarad Bioscience Company, USA). 
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HLA TYPING 
Patients were genotyped for HLA class DRB1 and DQB1 molecules. A 
Dynal Allset+ SSP DR low resolution kit (Dynal Biotech Ltd, Wirral, UK), 
a Dynal Allset+ SSP DQ low resolution kit, a Dynal Allset+ SSP DQB103 
and Dynal Allset+ SSP DQA1 were used for typing. Results were obtained 
after a 2% agarose gel electrophoresis.  
 
DUODENAL BIOPSY AND IMMUNOHISTOCHEMICAL 
ANALYSIS 
Biopsy specimens from duodenum were obtained by upper 
gastrointestinal endoscopies or by Watson biopsy device. At least three 
small intestinal biopsy specimens were obtained. Two fragments were  
fixed in 10% formalin, embedded in paraffin wax, sectioned at 5 µm 
thickness and stained with hematoxylin-eosin. The remaining fragment was 
immediately embedded in optimal cutting temperature compound (OCT- 
BioOptica), stored in liquid nitrogen. For the immunohistochemical study, 
biopsy specimens cryostat sections were cut at 4 µm and fixed in acetone 
for 10 min. After a 20 min pre-incubation with normal rabbit serum (1:100, 
Dako), sections were covered for 1 hr with anti-CD3 (1:200; Dako), anti-
CD25 (1:20; Dako), anti-TCRγδ (1:80; Thema), anti HLA-DR (1:10; 
Dako) and anti-CD54 (ICAM-1) (1:200; Dako) monoclonal antibodies, 
followed by rabbit anti-mouse immunoglobulins for 30 min. Monoclonal 
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antibodies were diluted in Tris pH 7.4, all incubations were performed at 
room temperature in a humid chamber. As a negative control, primary 
antibody was replaced with mouse IgG2a/IgG1 (1:100; Dako). After 
washing with Tris pH 7.4, the sections were layered with monoclonal 
mouse PAP (peroxidase-antiperoxidase) (1:100; Dako) for 30 min. 2-
amino-9-ethyl-carbazole (AEC) (Sigma) was used as peroxidase substrate. 
Finally, sections were counterstained with Mayer’s hematoxylin and 
mounted with Aquamount (BDH, Poole, England). 
The density of cells expressing CD3 and TCRγδ+ in the intraepithelial 
compartment was determined by counting the number of stained cells per 
mm epithelium. Cut-off values for CD3+ and TCRγδ+ cells are 35 
mm/epithelium and 3,2 mm/epithelium  respectively.  
The number of cells expressing CD25 in the lamina propria was 
evalutated within a total area of 1 mm2 of lamina propria. Cut-off value for 
CD25+ cells  is 4 mm2 lamina propria. 
Staining of cells expressing HLA-DR and ICAM-1, in the crypt and the 
lamina propria respectivaly was graded as weak, moderate or strong. Slides 
were analysed by two observers who were blinded. 
 
RNA EXTRACTION AND cDNA PREPARATION  
RNA was extracted from biopsy specimens using 1 mL of a monophasic 
solution of phenol and guanidine isothiocyanate (Trizol, Invitrogen Italia 
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SRL) and chloroform, followed by isopropanol (Sigma-Aldrich SRL) 
precipitation. The integrity of RNA was checked by electrophoresis on a 
1.5% agarose gel. A constant amount of total  RNA (0.5-1 µg) was retro-
transcribed into complementary cDNA in a 20 µl reaction mixture 
containing 50 mM Tris, pH 8.3, 75 mM KCl, 3 mM MgCL2, 500 µM each 
of dATP, dCTP, dTTP, and dGTP, 10 mM DTT, 0.5 µg oligo (dT) and 100 
U MMLV-RT (Invitrogen Life Technologies). RNA was retro-transcribed 
into cDNA at 42° C for 60 min, the reaction was stopped at 70° C for 10 
min and then the samples were cooled in ice. 
 
ANALYSIS OF mRNA EXPRESSION BY QUANTITATIVE RT-
PCR TAQ-MAN 
Real time PCR was performed using TaqMan probes/primers developed 
by BioRad (Milan) on demand. Quantification was performed in duplicate 
wells using Biorad reagents (Supermix) for Icycler iQ Real Time PCR 
detection system (Biorad, Milan). L32 gene RNA was used as an 
endogenous control. As a calibrator sample we used human peripheral 
blood mononuclear cells stimulated with lypopolisaccharide (1mg/ml) in 
RPMI for 2 hours. In each experimental plate we analysed in the same 
experimental conditions the RNA marker and the house-keeping gene of 
both the patient and the calibrator sample. Real-time PCR analysis was 
conduced using 5µl di cDNA in a total reaction volume of  50µl 
 132
conteining: 1.5 U Platinum Taq DNA Polymerase, 20 mM Tris-HCl (pH 
8.4), 50 mM KCl, 3 mM MgCl2, 200 µM of each dATP, dCTP, dGTP, 400 
µM dUTP, 1 U UDG (Platinum Quantitative SuperMix-UDG, Invitrogen 
Life Technologies), 0.2 µM of each primer and 0.2 µM probe. Samples 
were initially warmed to 50°C for 2 min, then the Taq DNA polymerase 
was activated by heating to 95° C for 2 min. PCR amplification was 
performed using the following conditions: 35-45 cycles of denaturation for 
15 s at 95°C,  annealing 1 min at 58°C for IFN γ, L32 and at 57° C for IL-
2, IRF-1, T-bet, L32). A calibration curve was created by two fold dilution 
with the calibrator sample for the RNA marker and for the L32 gene. 
Once completed the amplification the iQ cycler program calculated 
the efficiency of the experiment. The quantification of the RNA marker 
was analysed by a comparative threshold cycle (CT) method. ∆CT stands for 
the difference between CT of the marker gene and the house-keeping L32 
gene. ∆∆CT stands for the difference between CT of the analysed sample 
and the CT of the calibrator sample. Calculation of 2-∆∆CT then gives the 
relative amount of the analysed sample compared to the calibrator both 
normalised to the endogenous control L32. This calculation was obtained 
by a Real Time quantification program kindly developed by BioRad.  
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ISOLATION OF LYMPHOCYTES FROM SMALL INTESTINAL 
BIOPSIES 
Mucosal explants were either immediately incubated in a sterile tissue  
cultured dish (35 x 10 mm Falcon, Becton Dickinson, France) for a 1 h and 
30 min period at 37°C in RPMI 1640 medium (Cambrex, Belgium), 
without serum, with 1mg/ml Collagenase-A (Roche). In order to promote 
intra-cellular cytokine retention, Brefeldin A (BFA) (10 ug/ml, Sigma-
Aldrich) was added during the incubation.  
 
INTRACELLULAR CYTOKINE DETECTION BY FLOW 
CYTOMETRY 
Cells obtained from fresh biopsies were washed and labelled with 
conjugated mABs  against surface antigens: an  PE-Cy5-anti-
CD3antibody(UCHT1), FITC-anti-CD56 antibody(NCAM16.2), Cy-anti 
CD4  antibody (RPA-T4) and anti-CD25 antibody (M-A251) all purchased 
from BD (Pharmingen, San Diego, CA, USA). Appropriate isotype-
matched control antibodies(BD) were included in all experiments. After 
washing twice with PBS,  cells were fixed and permeabilized  with 
Cytofix/cytoperm (BD) according to the manufacturer’s instructions, 
followed by staining with PE-anti IL10 antibody (JES3-9D7) (BD 
Biosciences) or FITC-anti Foxp3 antibody (eBioscience) or Alexa 488-
anti-IL4antibody(8D4-8) (BD Biosciences) in permeabilization buffer and 
 134
then the cells were analyzed by a flow cytometer  FACSCalibur using 
CellQuest Software (Becton Dickinson).  
A first gate was performed on the basis of forward and side scatter 
profiles. Large granular cells were excluded in our gated population 
because of their very high side scatter. 
 
INTESTINAL DEPOSITS OF ANTI-TG2 ANTIBODIES  
Fixed in acetone, 5 µm frozen sections of each patient were examined by 
double immunofluorescence. After a 15 min preincubation with rabbit 
normal serum (1:100, Dako), the sections were covered with a monoclonal 
mouse antibody against guinea pig TG2 (CUB 7402) (1:200, NeoMarkers)  
for 1h at room temperature in a humid chamber. The sections were washed 
in PBS and incubated with a mixture of fluorescein isothiocyanate (FITC)-
labelled rabbit antibody against human IgA and IgM (1:100, Dako), to 
detect (in green) IgA and IgM deposits, and R-phycoerythrin (RPE)-
labelled rabbit anti-mouse antibody (1:40, Dako), to detect (in red) TG2, 
for 30 min in the dark. Finally, the section were washed several times in 
PBS and mounted by glycerol/PBS (1:10). The colocalization images of 
IgA and IgM mucosal deposits and TG2 that resulted in yellow  were 
analysed by a confocal microscopy (LSM510, Zeiss).  
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DIETARY ASSESSMENT 
The patients underwent a nutritional evaluation with the calculus of daily 
gluten intake amount and calcium, compared with a control population 
matched for age and sex. This evaluation was made with a “frequency 
questionnaire” and alimentary history. The amount of gluten introduced 
with aliments was calculated multiplying the total of vegetal protein for 0.8 
(standard factor) (van Overbeek FM 1997).   
 
BOWEL INFLAMMATORY INDEX 
Measurement of fecal calprotectin 
 
A stool specimen was collected by each subject using a disposable 
plastic bucket-type device to avoid contact with toilet water and simplify 
laboratory sampling. Only pre-endoscopy fecal samples were analyzed. 
Samples were stored at -20°C and thawed at room temperature before 
testing. The fetal calprotectin (FC) values were analyzed by a commercially 
available enzyme-linked immunosorbent assay (ELISA) (Calprest, 
Eurospital Spa, Trieste, Italy). The size of the samples is substantially 
reduced from 5g to 50-100 mg and FC levels are easily calculated from a 
standard curve and expressed as µg /g of stools. The cut off level of FC is  
95.3 µg/g (Berni Canani R 2004).  
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   Cellobiose/Mannitol Small Intestinal Permeability Ratio 
An oral load of two sugars (cellobiose 5 g and mannitol 2 g) was given 
in 100 mL of water (270 mOsm) to fasting subjects. Urine passed over a 5 
hour period was collected and stored at -20°C. Cellobiose and mannitol 
were measured, as previously described (Troncone R 1994). The final 
value resulted from the ratio of the recovered percentages of the two 
sugars, 0.023 is cutoff value.  
Computerised bone mineralometry 
We evaluated bone quality, measured as amplitude-dependent speed of 
sound (Ad-SoS) by quantitative ultrasound. 
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CONCLUSIONS 
In the last decade, it has become increasingly evident that CD 
encompasses a large spectrum of clinical manifestations that range from 
serious symptomatic forms to completely asymptomatic forms. At the same 
time, from a histological point of view, it goes from the typical severe 
lesions of duodenal mucosa to forms characterized by minor degrees of 
enteropathy.  
In clinical practice, by increased diagnostic efficiency of serum CD-
related autoantibodies measurements and increased attention for CD than in 
the past, it is increasingly more common to find patients who have serum 
positivity for CD autoantibodies but whose duodenal mucosa shows a 
normal histological appearance. The potential CD is a patient with anti-
endomysium antibodies (EMA) and/or anti-human tissue transglutaminase 
antibodies (anti-TG2) in serum, but a normal  mucosal architecture at the 
intestinal biopsy examination. Good markers of potential CD include subtle 
pathological alteration such as increased density of intraepithelial 
lymphocytes expressing γδ TCR, signs of activated mucosal cell-mediated 
immunity (such as expression of CD25 and B7 by lamina propria 
mononuclear cells), coeliac-like intestinal antibody pattern.  
The patients with minor degrees of enteropathy (potential or early-
developing CD) do not fulfill the traditional ESPGHAN diagnostic criteria. 
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In these case, the diagnosis of disease still rely on a combined approach 
based of clinical criteria,  histology, serology and genetics. Moreover, a 
revision of the current ESPGHAN criteria might be useful, as has already 
been frequently suggested, but it should be evidence-based.  
From a clinical practical point of view, there are no clear guidelines as 
to how best to deal with potential CD subjects, because it is little known 
about the natural history of patients with minor inflammation. More 
informations are also needed on the features influencing the degree of 
gluten-dependent inflammation, on the markers predictive of evolution to 
frank CD and on the health risks they are exposed to, if left on a normal 
gluten-containing diet. At this propose, we showed that the potential CD is 
a condition mainly seen in first-degree relatives (28%) and patients with 
autoimmune disorders (16%). In our cohort anti TG2 titres was lower than 
that showed by CD with atrophy, in 44% showed a fluctuation of 
antibodies titres with transient negativity for EMA or anti-TG2 values, 
while in a 7.4% they returned persistently and completely negative. Finally, 
duodenal mucosa can remain normal for several years despite the presence 
of CD associated antibodies. These data are very interesting, but they are 
not conclusive. A prospective and randomized study with longer follow-up 
is necessary. 
For the first time, in these same patients with potential CD we studied in 
the duodenal mucosa immunological markers to clarify the early events 
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leading to enterophaty. In potential CD mucosa T cells are activated and 
committed Th1 as supported by the increased expression of IL-2, T-bet and 
IFNγ. Likely, in the early phase of disease IL-10 play a crucial role to 
prevent the progression towards a complete mucosal damage. In fact, the 
levels of IL-10 were significantly increased in this group of patients (T0 
Marsh) than controls, while in T1 Marsh  group they were reduced. In 
particular the ratio between IL 10 and IFN-γ  was increased in group T0 if 
compared to active coeliac patients and group T1. Moreover, a further data 
that support the hypothesis that the regulatory mechanisms might 
downregulate T cell mediate immuno-response in the early phase of CD 
enterophaty is the increased number of CD4+CD25+FOXP3+ regulatory T 
cells. The subsequent events leading  to failure of these regulatory 
mechanisms remain  to know.  
In clinical practice, another particular condition is the CD in patients 
with selective IgA deficiency. Screening for CD is a special challenge in 
IgAD since the IgA class CD associated autoantibodies are not produced. In 
addition, enhanced T cell activation is present in the intestine of IgAD 
making difficult the differential diagnosis with potential CD. To find 
markers that could improve the diagnostic accuracy of CD in  these 
subjects, we studied the density of intraepithelial γδ T cells and the 
deposition of anti TG2 IgM antibodies in duodenal mucosa of IgAD 
patients. We found that deposited IgM anti TG2 antibodies are present in 
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only 14% of jejunal specimens of potential CD probably because the low 
titre/affinity. Of crucial importance for the diagnosis of CD in IgAD 
patients remains the finding of serum IgG CD-associated autoantibodies. 
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